WO2009085757A2 - Radiopaque alloy and medical device made of this alloy - Google Patents

Radiopaque alloy and medical device made of this alloy Download PDF

Info

Publication number
WO2009085757A2
WO2009085757A2 PCT/US2008/086994 US2008086994W WO2009085757A2 WO 2009085757 A2 WO2009085757 A2 WO 2009085757A2 US 2008086994 W US2008086994 W US 2008086994W WO 2009085757 A2 WO2009085757 A2 WO 2009085757A2
Authority
WO
WIPO (PCT)
Prior art keywords
concentration
alloy
radiopaque
atomic percent
nickel
Prior art date
Application number
PCT/US2008/086994
Other languages
French (fr)
Other versions
WO2009085757A3 (en
Inventor
Valery Diamant
Dan Koren
Alexander Lotkov
Vladimir Sivokha
Liydmila Meysner
Viktor Grishkov
Vladimir Voronin
Original Assignee
Cook Incorporated
Lithotech Medical Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cook Incorporated, Lithotech Medical Ltd. filed Critical Cook Incorporated
Priority to EP08867178A priority Critical patent/EP2238270A2/en
Publication of WO2009085757A2 publication Critical patent/WO2009085757A2/en
Publication of WO2009085757A3 publication Critical patent/WO2009085757A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C22METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22CALLOYS
    • C22C19/00Alloys based on nickel or cobalt
    • C22C19/03Alloys based on nickel or cobalt based on nickel
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/02Inorganic materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/18Materials at least partially X-ray or laser opaque
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/02Inorganic materials
    • A61L31/022Metals or alloys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/18Materials at least partially X-ray or laser opaque
    • CCHEMISTRY; METALLURGY
    • C22METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22CALLOYS
    • C22C14/00Alloys based on titanium
    • CCHEMISTRY; METALLURGY
    • C22METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22FCHANGING THE PHYSICAL STRUCTURE OF NON-FERROUS METALS AND NON-FERROUS ALLOYS
    • C22F1/00Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working
    • C22F1/10Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working of nickel or cobalt or alloys based thereon
    • CCHEMISTRY; METALLURGY
    • C22METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22FCHANGING THE PHYSICAL STRUCTURE OF NON-FERROUS METALS AND NON-FERROUS ALLOYS
    • C22F1/00Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working
    • C22F1/16Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working of other metals or alloys based thereon
    • C22F1/18High-melting or refractory metals or alloys based thereon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00Materials characterised by their function or physical properties
    • A61L2400/16Materials with shape-memory or superelastic properties

Definitions

  • This invention is generally in the field of metallurgy, and more specifically relates to radiopaque alloys and medical devices comprising these alloys.
  • Shape memory alloys are the group of metallic materials that exhibit a shape-memory effect (SME).
  • SME shape-memory effect
  • TMT thermoelastic martensitic transformation
  • martensitic transformations there exists a parent, high-temperature austenite crystallographic phase having higher symmetry. As the temperature lowers, the crystallographic structure changes to martensite, a phase with lower symmetry. It is possible for multiple variants or orientations of the martensite phase to be present in the same material.
  • FIG. 1 and Fig. 2 schematically illustrate the forward and reverse phase transformations in the strain-temperature ( ⁇ -T) plane and in the stress-strain ( ⁇ - ⁇ ) plane, respectively.
  • M s martensite start temperature
  • M f martensite finish temperature
  • a s austenite start temperature
  • a f austenite finish temperature
  • Fig. 2 corresponds to the case when an exemplary SMA is deformed at a constant temperature.
  • This temperature is preferably in the range between A f and M d where A f is the previously defined austenite finish temperature, and M d marks the maximum temperature at which martensite can be induced by an applied stress without substantially plastically deforming the austenite phase.
  • a f is the previously defined austenite finish temperature
  • M d marks the maximum temperature at which martensite can be induced by an applied stress without substantially plastically deforming the austenite phase.
  • the martensite phase starts to form in the material.
  • the line from point A to point B represents the elastic deformation of a SMA.
  • the strain or deformation is no longer proportional to the applied stress, and it is in the region between point B and point C that the stress-induced transformation of the austenitic phase to the martensitic phase begins to occur.
  • the material enters a region of relatively constant stress with significant deformation or strain. This constant stress region is known as the loading plateau, and it is in this plateau region C-D that the transformation from austenite to martensite occurs.
  • alloys having shape memory effect and superelasticity such as silver-cadmium (Ag-Cd), gold-cadmium (Au-Cd), gold-copper- zinc (Au-Cu-Zn), copper-aluminum-nickel (Cu-Al-Ni), copper-gold- zinc (Cu-Au- Zn), copper-zinc (Cu-Zn), copper-zinc-aluminum (Cu-Zn-Al), copper-zinc-tin (Cu-Zn-Sn), copper-zinc-xenon (Cu-Zn-Xe), iron beryllium (Fe 3 Be), iron platinum (Fe 3 Pt), indium-thallium (In-Tl), iron-manganese (Fe-Mn), nickel-aluminum (Ni- Al), copper based alloys, as well as Ni-Ti (nickel-titanium) based alloys.
  • silver-cadmium Au-Cd
  • Au-Cd gold-copper- zinc
  • Nitinol equiatomic or near-equiatomic nickel-titanium alloys
  • Ti-Ni alloys can exhibit 50-60% elongation and have a tensile strength up to 1000 MPa.
  • Ti-Ni transforms from a ductile martensite phase with B 19' structure to a stiff er austenite phase of B2 structure.
  • Ti-Ni shifts in structure from B2 to B 19'.
  • M s is approximately within the range of 60°C-65°C, and A s is approximately 95 0 C-IOO 0 C.
  • SMAs may be practically used for actuators, pipe couplings, switches or the like by taking advantages of their shape memory properties. Products that rely on the superelasticity of the SMAs include, but are not limited to, antennas, eye glass frames, wires of brassieres, orthodontic archwires, etc.
  • Various proposals have also been made to employ SMAs in the medical field. For example, U.S. Pat. No. 3,620,212 to Fannon et al. proposes the use of an SMA intrauterine contraceptive device, U.S. Pat. No. 3,786,806 to Johnson et al. proposes the use of an SMA bone plate, U.S. Pat. No.
  • Radiopacity can also be improved by alloy addition.
  • a challenge for medical device applications is the preparation of a suitably radiopaque Ti-Ni alloy that also displays superelastic behavior around body temperature. It would be advantageous to develop a radiopaque nickel-titanium alloy that provides a substantial improvement in radiopacity compared to binary Ti-Ni alloys without a loss in superelastic properties.
  • a radiopaque nickel-titanium alloy that may provide increased radiopacity compared to binary Ti-Ni alloys.
  • the radiopaque alloy preferably displays superelastic behavior and shape memory properties suitable for medical device applications in the human body.
  • a medical device comprising the radiopaque nickel-titanium alloy.
  • the alloy comprises at least one radiopaque alloying element to provide a desired radiopacity of the alloy.
  • the alloy further comprises at least one additional alloying element to maintain the superelasticity properties of the alloy within a desired superelasticity temperature interval.
  • the alloy may also comprise at least one further alloying element to provide instability of the alloy to a martensitic transformation in a predetermined instability temperature interval.
  • the alloy includes titanium at a concentration of from about 48 to about 52 atomic percent, and at least one radiopaque alloying element selected from the group consisting of palladium, platinum and gold, where palladium is at a concentration of from about 15 to about 35 atomic percent, and platinum and gold are at a concentration of from about 10 to about 35 atomic percent.
  • the alloy also includes at least one additional alloying element selected from selected from the group consisting of aluminum, chromium and zirconium, where aluminum and chromium are at a concentration of from over 0 to 2 atomic percent and zirconium is at a concentration of from over 0 to about 6 atomic percent, and the balance of the alloy is nickel.
  • the alloy consists essentially of titanium at a concentration of from about 48 to about 52 atomic percent; at least one radiopaque alloying element selected from the group consisting of palladium, platinum and gold, where palladium is at a concentration of from about 15 to about 35 atomic percent, and platinum and gold are at a concentration of from about 10 to about 35 atomic percent; at least one additional alloying element selected from the group consisting of iron and cobalt at a concentration of from about 0.5 to about 8 atomic percent; at least one further alloying element selected from the group consisting of aluminum, chromium and zirconium, where aluminum and chromium are at a concentration of from over 0 to about 2 atomic percent, and zirconium is at a concentration of from over 0 to about 6 atomic percent; and nickel and inevitable impurities as a balance.
  • the alloy includes at least one radiopaque alloying element at a concentration of from about 10 at.% to about 20 at.%, where the radiopaque alloying element is selected from the group consisting of gold, platinum, and palladium.
  • the nickel-titanium alloy also includes at least one additional alloying element selected from the group consisting of aluminum, chromium, cobalt, iron, and zirconium, where the additional alloying element has a concentration of from about 0.5 at.% to about 4 at.%.
  • the alloy includes titanium at a concentration of from about 48 at.% to about 52 at.% and the balance of the alloy is nickel.
  • the alloy has a radi opacity greater than that of a binary nickel-titanium alloy and exhibits a recoverable strain of at least about 2% upon removal of a deforming stress at about body temperature.
  • the alloy includes a radiopaque constituent comprising one or more radiopaque elements selected from the group consisting of gold, platinum, and palladium, where the radiopaque constituent has a concentration of from about 10 at. % to about 35 at. %.
  • the medical device has at least one component comprising a radiopaque alloy having shape memory and superelastic properties, where the radiopaque alloy consists essentially of titanium at a concentration of from about 48 to about 52 atomic percent, at least one element selected from the group consisting of palladium, platinum and gold, where palladium is at a concentration of from about 15 to about 35 atomic percent, and platinum and gold are at a concentration of from about 10 to about 35 atomic percent, at least one element selected from the group consisting of iron and cobalt at a concentration of from about 0.5 to about 8 atomic percent, and at least one element selected from selected from the group consisting of aluminum, chromium and zirconium, where aluminum and chromium are at a concentration of from over 0 to about 2 atomic percent and zirconium is at a concentration of from over 0 to about 6 atomic percent, with nickel and inevitable impurities as the balance.
  • the medical device comprises at least one component including a radiopaque alloy having shape memory and superelastic
  • Fig. 1 schematically illustrates a complete thermodynamic cycle of a shape memory alloy in the strain-temperature ( ⁇ -T) plane
  • Fig. 2 schematically illustrates a complete thermodynamic cycle of a shape memory alloy in the stress-strain ( ⁇ - ⁇ ) plane
  • Figs. 3A-3C are exemplary phase diagrams of martensitic transformations for Ti 50 oNi 5O 0-x Pd x , Ti 50 oNi 5O o -x Pt x and Ti 50 oNi 5O 0-x Au x compositions, respectively;
  • the selection of alloying elements for a radiopaque Ti-Ni alloy composition was influenced by the desire to retain the biocompatibility properties of the Ti-Ni alloys, improve the radi opacity of the Ti-Ni alloys, obtain superelastic behavior from the Ti-Ni alloys, and shift the phase transformation temperatures (e.g., A f ) to a range appropriate for biomedical use of a device (or article) made of such alloys.
  • phase transformation temperatures e.g., A f
  • the alloy may include one or more additional alloying elements (e.g., Al, Zr, Cr, Fe, and/or Co) to aid in reducing the phase transformation temperatures to values suitable for an insertable or implantable medical device.
  • additional alloying elements e.g., Al, Zr, Cr, Fe, and/or Co
  • the alloys described herein may be used for the production of medical devices that exhibit both radiopacity and superelastic effects, since the alloys preferably contain at least one radiopaque element and at least one additional alloying element that promotes the retention of superelastic properties in a temperature range suitable for use in the human body.
  • a shape memory alloy based on titanium nickelide and having radiopaque and superelastic properties including: at least one radiopaque element replacing a part of nickel and/or titanium in such amount so as to provide a desired radiopacity of the alloy without causing the destruction of a structure of high-temperature B2-phase; at least one alloying element replacing a part of nickel and/or titanium in such amount so as to maintain the superelasticity properties of the alloy within a desired superelasticity temperature interval; and at least one alloying element replacing a part of nickel and/or titanium in such amount so as to provide instability of the alloy to a martensitic transformation in a predetermined instability temperature interval.
  • TiNi-TiPd TiNi-TiPt
  • TiNi-TiAu TiNi-TiAu
  • exemplary phase diagrams of martensitic transformation temperatures for Ti 50 oNiso o -x Pd x , Ti 50 0 Ni 5 o o- ⁇ Pt x and Ti 500 Ni 50 o- ⁇ Au x compositions are shown respectively.
  • the concentration (x) of Pd increases from 0 to about 7 atomic percent
  • the martensite start temperature M s and martens ite finish temperature M f of the Ti 500 Ni 50 o- x Pd x alloy both decrease.
  • the further addition of Pd increases the phase transformation temperatures M s and M f .
  • phase diagram of martensitic transformation for Ti 50 oNi 5O o- ⁇ Au x shows similar behavior (see Fig. 3C).
  • the transformation temperatures M s and M f slightly decrease when the concentration (x) of Au increases from 0 to about 3 atomic percent. When x increases beyond this range, the phase transformation temperatures increase, first gradually and then more rapidly beyond a concentration of about 20 at.% Au.
  • a f when the alloy is intended for use in a medical device inserted or implanted within a living body, it may be advantageous for A f to be less than or equal to the temperature of the living body (e.g., 37 0 C).
  • the temperature of the living body e.g. 37 0 C.
  • self- expanding stents are generally compressed to a reduced diameter and restrained within a tubular sheath for delivery within a body vessel; once in place at a treatment site, they are deployed superelastically to an expanded configuration so as to contact the vessel wall.
  • one or more quaternary alloying elements may be added to the ternary alloy compositions Ti 500 Ni 500-x Me x (where Me is selected from Pd, Pt, Au) to reduce the transformation temperatures to the desired temperature range.
  • the additional alloying elements do not deteriorate the radiopacity of the alloy.
  • the radiopacity of the alloy aids in positioning the device in the desired location in the body passageway during delivery and deployment. It is also preferred that the quaternary alloying elements do not detrimentally affect the superelastic and/or mechanical properties of the Ti 50 0 Ni 50 O-X Me x alloy.
  • such a quaternary alloying element can be either iron (Fe) or cobalt (Co).
  • intermetallic compounds with the B2 superstructure may be formed, i.e., their structure is similar to that of the high-temperature B2-phase of TiNi.
  • TiNi alloyed with the atoms of Fe and/or Co instead of Ni may allow the B2-phase structure of the material to be retained.
  • Figs. 4A and 4B exemplary phase diagrams of martensitic transformation for Ti 500 Ni 500-x Fe x , and Ti 500 Ni 50 0-x Co x compositions are shown, respectively. Alloying of TiNi with atoms of Fe and Co may cause a decrease in the martensitic transformation temperatures. As illustrated in Fig. 4A, the martensite finish temperature M f of Ti 500 Ni 500-x Fe x drastically decreases by about 200 0 C when x changes from 0 to about 3 atomic percent. The martensite start temperature M s of the Ti 500 Ni 50 0-x Fe x alloy behaves in a similar manner at increasing iron concentrations. Likewise, as illustrated in Fig.
  • the temperature of martensitic transformation M f of Ti 50 0 Ni 500-x Co x drastically decreases by about 200 0 C when x changes from about 0 to 7 atomic percent.
  • the martensite start temperature M s of the Ti 50 oNi 50 0-x Co x alloy decreases by about 75 ° C over the same concentration range.
  • these alloying elements may modify the sequence of martensitic transformation from B2 ⁇ Bl9'm TiNi to B2 ⁇ R ⁇ B19'in Ti 500 Ni 50 0-x Fe x and/or Ti 50 0 Ni 50 0 - x Co x , which may have a favorable effect on the exhibition of the superelasticity effect.
  • Applicants also believe that when atoms of Ni in TiNi are substituted with both the radiopaque alloying elements Pd, Pt and/or Au together with alloying elements Fe and/or Co, the alloying elements of these two groups independently influence the temperature of martensitic transformation.
  • atoms of Pd introduced instead of atoms of Ni in TiNi may increase the temperature of martensitic transformations in accordance with the diagram of martensitic transformations TiNi-TiPd, while atoms of Fe may decrease the temperature of martensitic transformations in accordance with the diagram of martensitic transformations TiNi-TiFe.
  • the concept of producing a radiopaque NiTi-based alloy exhibiting superelastic behavior around body temperature i.e., having an austenite finish temperature A f of less than or equal to 37°C, is as follows.
  • TiNi is preferably alloyed with one or more components selected from Pd, Pt and Au.
  • the one or more components replace a part of nickel and/or titanium and may sufficiently increase the radiopacity without causing the destruction of the superstructure of the high-temperature B2-phase of TiNi.
  • the amount of the alloying elements Mel exceeds 15 atomic percent. Even more preferably, the amount of the alloying element Mel exceeds 20 atomic percent when Mel is Pd.
  • the radiopacity of the TiNiMeI alloy (when Mel is selected from Pt and Au) can sufficiently be improved when the amount of the alloying elements Mel exceeds 10 atomic percent.
  • the amount of the alloying elements Mel exceeds 15 atomic percent when Mel is Pt.
  • the amount of the alloying elements Mel in the TiNiMeI alloy is in the range of about 15% to 35% (by atomic percent) when Mel is Pd, and in the range of about 10% to 35% (by atomic percent) when Mel is Pt and/or Au.
  • the adding of the alloying elements Mel may raise the phase transformation temperatures of the alloy. Therefore, in order to return the phase transformation temperatures to the desired temperature interval (e.g., A f to less than or equal to human body temperature) without detrimentally affecting the radiopacity, at least one component of Me2 selected from Fe and/or Co can be further added to the alloy by replacing a part of nickel and/or titanium.
  • a preferred amount of Fe and/or Co in TiNiMelMe2 alloy can be in the range of about 0.5% to about 8% (by atomic percent).
  • one or more components of Me3 selected from aluminum (Al) and chromium (Cr) can be further added to the TiNiMe lMe2 alloy by replacing a part of nickel and/or titanium.
  • adding Al and/or Cr may provide a wide temperature interval of instability of the intermetallic compound to the martensitic transformation.
  • adding Al and/or Cr may extend the temperature interval of instability to a range wider than 50 degrees. In this case, the instability temperature interval may be greater than the instability temperature interval of the equiatomic Ti-Ni alloy.
  • a preferred amount of Al and/or Cr in the TiNiMe lMe2Me3 alloy is less than about 2 at. %. Applicants believe that when the amount of Al or Cr exceeds 2 at. %, secondary phases may be formed in the alloy that may adversely affect the completeness of the phase transformations and, accordingly, may deteriorate the shape memory and superelastic properties of the material.
  • zirconium (Zr) can be added either to the TiNiMe lMe2 alloy or to the TiNiMe lMe2Me3 alloy by replacing a part of nickel and/or titanium. Specifically, Zr can be dissolved in the alloy in amounts much greater than Al and Cr.
  • Zr can be dissolved in the amount of about 6 at. %, and preferably in the amount of 4 at. %.
  • the addition of zirconium does not lead to the formation of a secondary phase (in contrast to the effect expected when atoms of Al and Cr are added).
  • adding zirconium may also provide a wide temperature interval of instability of the Ti-Ni alloy to martensitic transformation.
  • the expression "wide temperature range” herein refers to a temperature interval greater than 50 degrees.
  • Fig. 5B illustrates exemplary phase diagrams of martensitic transformation for Ti 500-X Ni 5O oZr x compositions.
  • the martensite start temperature M s and finish temperature M f both decrease.
  • the further addition of Zr increases the phase transformation temperatures M s and M f .
  • the transformation temperatures M s and M f correspond to those of binary Ti 500 Ni 500 alloy.
  • the martensitic transformation temperatures further increase.
  • phase transformation temperatures can be achieved by departing from the stoichiometric relationship between Ni and Ti in the Ti 50 0 Ni 50 0 alloy.
  • Fig. 6A shows an exemplary phase diagram of martensitic transformations in alloys Ti 50-x Ni 50+x quenched from 1073 0 K; and
  • Fig. 6B shows an exemplary phase diagram of martensitic transformations in alloys Ti 5 o -x Ni 5 o +x annealed at the temperature of 1073 0 K (for 1 hour) and then cooled to room temperature.
  • the martensitic transformation temperatures of the TiNi alloy decrease.
  • boron (B) may be further added to the NiTi-based alloys described herein by replacing a part of nickel and/or titanium.
  • a preferred amount of B in the TiNi-based alloys can be in the range of about 0.05 at.% to about 0.2 at.% .
  • the radiopaque nickel-titanium alloy includes: at least one radiopaque alloying element at a concentration of from about 10 at.% to about 20 at.%, where the radiopaque alloying element is selected from the group consisting of gold, platinum, and palladium; at least one additional alloying element selected from the group consisting of aluminum, chromium, cobalt, iron, and zirconium, where the additional alloying element has a concentration of from about 0.5 at.% to about 4 at.%; titanium at a concentration of from about 48 at. % to about 52 at.%; and nickel as the balance.
  • the concentration of the additional alloying element may be in the range of from about 0.5 at.% to about 1.2 at.%.
  • the nickel has a concentration of from about 29 at.% to about 52 at.%
  • the radiopaque nickel-titanium alloy may include gold at a concentration of about 20 at.%, iron at a concentration of about 0.5 at.%, and zirconium at a concentration of about 1 at.%.
  • the radiopaque nickel-titanium alloy may include gold at a concentration of about 10 at.%, iron at a concentration of about 1.2 at.%, and zirconium at a concentration of about 1 at.%.
  • the radiopaque nickel-titanium alloy may include gold at a concentration of about 15 at.% and aluminum at a concentration of about 1.2 at.%.
  • the radiopaque nickel-titanium alloy may include gold at a concentration of about 15 at.%, and chromium at a concentration of about 1 at.%.
  • the radiopaque nickel-titanium alloy may include platinum at a concentration of about 15 at.%, iron at a concentration of about 4 at.%, and zirconium at a concentration of about 1 at.%.
  • the radiopaque nickel- titanium alloy may comprise: a radiopaque constituent comprising one or more radiopaque elements selected from the group consisting of gold, platinum, and palladium, where the radiopaque constituent has a concentration of from about 10 at. % to about 35 at.
  • an additional constituent comprising one or more additional alloying elements selected from the group consisting of aluminum, chromium, cobalt, iron, and zirconium, where the additional constituent has a concentration of from about 0.5 at.% to about 13 at.%; titanium at a concentration of from about 48 at.% to about 52 at.%; and the balance nickel, wherein the alloy has a radiopacity greater than that of a binary nickel-titanium alloy and a recoverable strain of at least about 2% upon removal of a deforming stress at about body temperature.
  • the concentration of the radiopaque constituent is from about 10 at.% to about 20 at.% and the concentration of the additional constituent is from about 1 at.% to about 5 at.%.
  • the nickel has a concentration of from about 29 at.% to about 52 at.%.
  • the radiopaque constituent may be gold at a concentration of about 20 at.%, and the additional constituent may include iron and zirconium, where the additional constituent has a concentration of about 1.5 at.%.
  • the radiopaque constituent may be gold at a concentration of about 10 at.%, and the additional constituent may include iron and zirconium, where the additional constituent has a concentration of about 2.2 at.%.
  • the radiopaque constituent may be gold at a concentration of about 15 at.%
  • the additional constituent may include one of aluminum and chromium, where the additional constituent has a concentration in the range of from about 1.0 at.% to about 1.2 at.%.
  • the radiopaque constituent may be platinum at a concentration of about 15 at.%, and the additional constituent may include iron and zirconium, where the additional constituent has a concentration of about 5 at.%.
  • Phase transformation temperatures e.g., martensite start temperature
  • M 5 of a quaternary or quintary nickel-titanium alloy can be estimated on the basis of the known effect of each individual alloying element on the phase transformation temperatures of the binary TiNi system, assuming that the individual effects are cumulative in a multicomponent system, as described below.
  • a change in the martensite start temperature M s relative to the binary TiNi system can be derived for each alloying element (e.g., Au, Fe, and Zr) at the appropriate concentration using the data provided in Figs. 3 A to 5B, and then the respective changes may be summed as discussed in this and the related examples below.
  • alloying element e.g., Au, Fe, and Zr
  • the alloying element Fe can be added.
  • adding the alloying element Fe in the amount of 2.3 at.% by replacing 2.3 at.% Ni decreases M 5 from about +55 0 C for the binary TiNi alloy to about -75 0 C for the Ti 50 Ni 47 7 Fe 2 3 alloy.
  • One can also calculate a value ⁇ T Au + ⁇ T Fe » 80°C +( -130 0 C) -50 ° C which represents the estimated combined effect of 25 at.% Au and 2.3 at.% Fe on the binary TiNi system. Accordingly, M 5 (Ti 50 Ni 22 7 Au 25 0 Fe 2 3 ) « M 5 (TiNi) + ⁇ T Au + ⁇ T Fe « 55°C + (-50 0 C) « +5 ° C. Taking into account the hysteresis of the phase transformation temperatures (see Fig. 1) and assuming a temperature differential T 1 of approximately 30 0 C to 35°C, A f may be estimated to be « 35 0 C -40 0 C.
  • the transformation temperatures can be further reduced by adding the alloying element Zr in the amount of 1.0 at. % by replacing 0.5 at. % of Ti and 0.5 at. % of Ni.
  • adding the alloying element Zr in the amount of 1.0 at. % by replacing 0.5 at. % of Ti and 0.5 at. % Ni decreases M 5 to the temperature M 5 (Ti 49 5 Ni 49 5 Zr] 0 ) ⁇ 45°C from an assumed binary value of 55°C.
  • the temperature of the onset of the reverse martensitic transformation in such an alloy can be estimated as A f »20 o C-30 o C.
  • Example 1.1 The same procedure as described in Example 1.1 may be employed to estimate the transformation temperatures for a Ti 48 7 Ni 35 0 Au 15 0 Al 1 3 alloy.
  • alloying a binary TiNi alloy with a radiopaque alloying element Au in the amount of 15 at.% by replacing 15 at.% of nickel increases M 5 from about 55 "C for the binary TiNi system to approximately 100 0 C for the Ti 50 Ni 35 Au 15 alloy.
  • M 5 (Ti 50 Ni 35 Au 15 ) « 100°C and ⁇ T Au « (100°C - 55°C) 45°C.
  • the temperature M 5 of the multi-component Ti 48 7 Ni 35 0 Au 15 0 Al 1 3 alloy alloy can be estimated as M 5 ⁇ (M 5 (TiNi) + ⁇ T Au + AT A1 ) * ⁇ 55°C + 45°C + (-11 IT) ⁇ » -11°C, where M 8 of TiNi is assumed to be 55 ° C.
  • the temperature of the onset of the reverse martensitic transformation in such an alloy can be estimated as A f « 19°C-24°C.
  • Example 1.2 The same procedure as described in Example 1.2 may be employed to estimate the transformation temperatures for a Ti 48 7 Ni 35 oAu 15 QCr 1 0 alloy.
  • a binary TiNi alloy can be alloyed similar to Example 2 with a radiopaque alloying element Au in the amount of 15 at.% by replacing 15 at.% of nickel. As described in the previous example, this alloying increases M s from about 55°C to the temperature M 5 (Ti 50 Ni 35 Au 15 ) -100 °C (i.e., by ⁇ T Au « 45°C).
  • an alloying element such as Cr can be used.
  • adding Cr in the amount of 1.0 at.% by replacing 1.0 at.% of Ni decreases M 5 to the temperature M 5 (Ti 50 C )Ni 49 o 0 Cr 1 0 ) « -8O 0 C (i.e., by ⁇ T Cr ⁇ -135°C, assuming that the M 5 of TiNi is 55°C).
  • the temperature M 5 (Ti 50 0 Ni 34 0 Au 15 0 Cr 1 0 ) can be estimated to be about -35°C. Accordingly, the temperature of the onset of the reverse martensitic transformation for Ti 48 7 Ni 35 0 Au 15 0 Cri 0 can approximately be estimated as A f ⁇ -5°C to 0°C.
  • Suitable composition ranges for the radiopaque nickel-titanium alloy are presented in Table 1.
  • the alloys described hereinabove can be fabricated by melting Ti, Ni mixed with alloying elements according to the compositions suggested above.
  • the melting of the composition can be carried out by mixing all the alloying elements together and then applying elevated temperatures to the mixture.
  • the melting of the composition can be carried out by first mixing and melting only base alloying elements with a consequent cooling of this mixture, and then adding one or more secondary alloying elements and remelting the mixture one or more times again.
  • the mixture can, for example, be heated and molten in an induction furnace, arc furnace or other suitable oven in a protective atmosphere.
  • the mixture may be molten in a purified helium or argon atmosphere.
  • the melting can be carried out at a constant temperature, e.g. at a temperature within the temperature interval of about 1200 0 C to 1400°C.
  • the melting can be carried out by elevating the temperature at a rate of, for example, 5°C per minute to 50°C per minute from about room temperature to a temperature in the range of about 1200°C to 1400°C. Thereafter, the melt can be poured to a cooled mold, e.g.
  • Embodiments of the fabrication method described above were employed to produce 29 alloy compositions in the form of ingots or buttons. Three of the 29 alloys were binary Ti-Ni compositions.
  • alloys designated as numbers 4, 13, 14, 15, and 16 were selected from all of the melted compositions for further investigation. Alloys designated as numbers 4/2, 4/3, and 15/2 are remelts of alloys 14 and 15, respectively. As will be discussed below, substantial recoverable strains were obtained from stress-strain tests of each of these alloys. Preferably, the alloy has a recoverable strain of at least about 2% upon removal of a deforming stress at about body temperature. It is preferred that the recoverable strain is at least about 5%. It is believed that the selected alloys may have sufficient ductility to undergo further mechanical working into forms such as strip, wire or plate. [00103] Bars of specified dimensions were prepared from samples 4, 13, 14,
  • thermal treatments annealing, aging, etc.
  • thermal treatments may provide a means of varying the phase transformation temperatures of the alloys. This phenomenon can be associated with the formation of secondary phases and precipitates (distinguished from the B2 phase) during thermal processing.
  • Annealing and/or aging may provide dilution or precipitation of secondary phases.
  • the composition of the parent phase may be altered, and thus the phase transformation temperatures of the alloy may be changed.
  • correction of the phase transformation temperatures may be effected by a further thermal treatment of the alloy.
  • the specimens were tested in the as-cast state and/or following one or more annealing treatments. High temperature anneals of the specimens were conducted in a vacuum environment.
  • the mixture was molten in an arc furnace in a purified argon atmosphere (about 0.4 atm Ar) at a temperature of about 1300°C in a water-cooled copper mold.
  • the arc current was 500 A.
  • the melt was then cooled to a temperature of about 4O 0 C.
  • the ingot was remelted six times. After cooling between each remelt, the ingot was turned upside down. After the final cooling, bars having a rectangular cross-section of 1.2 mm by 1.2 mm and a length of 26.0 mm were fabricated and tested as described above to evaluate the superelastic behavior of the specimen.
  • Fig. 9 illustrates a stress-strain plot for measurements at the temperature of 18 0 C of a Ti 49 5 Ni 29 o Au 2 o 0 Fe 0 5 Z ⁇ 0 sample prepared as described above. The sample was heated at the temperature of 320°C over 30 minutes before the mechanical test. The plot shows a stress-strain hysteresis which is characteristic of superelastic behavior. As is apparent from the plot, the Ti 495 Ni 29 oAu 2O 0 Fe 05 Zr 1 0 alloy achieves a recoverable strain of 6.1% in response to the applied torsional stress of 195 MPa at a test temperature of 18°C. [00110] Referring to Fig.
  • Table 3 provides a summary of the recoverable strain values obtained for sample #4 from the stress-strain tests. Depending on the test temperature, heat treatment, and the maximum applied torsional stress ( ⁇ max ), recoverable strain values ( ⁇ res iii ence ) in the range of from 3.9% to 7.1% were obtained. Also given in the table is the residual plastic component of the deformation, ⁇ resi duai-
  • Ti 49 5 Ni 29 oAu 2O 0 Fe 0 5 Zr 1 0 alloy having an austenite finish temperature A f of less than about 17°C may be fabricated as described herein. Accordingly, it is concluded that superelastic behavior may be obtained at human body temperature
  • the alloy designated in Table 2 as #14 was fabricated as follows. A mixture was prepared from the following elements of the indicated purities: titanium, 99.9%; nickel, 99.99%; gold, 99.95%; iron, 99.95% and zirconium, 99.99%. The mixture weight was 50 g and it contained 17.761 grams of titanium, 16.548 grams of nickel, 14.607 grams of gold, 0.4970 gram of iron and 0.6765 gram of zirconium, which corresponds to the composition: 50.0 at. % Ti; 37.8 at.% Ni; 10.0 at.% Au; 1.2 at.% Fe; and 1.0 at.% Zr (Ti 500 Ni 37 8 Au 1O oFe 1 2 Zrj 0 ).
  • the application field of the alloy of the present invention is not limited to medicine.
  • the alloy can also be used for making thermo-sensitive actuating load-bearing elements and other constructions in instrument-making and radio-electronics, etc.

Abstract

A radiopaque alloy based on titanium nickelide and having shape memory and superelastic properties includes, according to one embodiment, at least one radiopaque alloying element selected from the group consisting of gold, platinum, and palladium at a concentration of from about 10 at.% to about 20 at.%, and at least one additional alloying element selected from the group consisting of aluminum, chromium, cobalt, iron, and zirconium, where the additional alloying element has a concentration of from about 0.5 at.% to about 4 at.%. The alloy includes titanium at a concentration of from about 48 at.% to about 52 at.%, and the balance of the alloy is nickel. The radiopaque alloy preferably exhibits superelastic behavior suitable for medical device applications in the human body.

Description

RADIOPAQUE ALLOY AND MEDICAL DEVICE MADE OF THIS ALLOY
RELATED APPLICATION
[0001] The present patent document claims the benefit of the filing date under 35 U.S.C. §119(e) of U.S. Provisional Patent Application Serial No. 61/016,055, which was filed on December 21, 2007, and is hereby incorporated by reference in its entirety.
FIELD OF THE INVENTION
[0002] This invention is generally in the field of metallurgy, and more specifically relates to radiopaque alloys and medical devices comprising these alloys.
BACKGROUND OF THE INVENTION
[0003] Shape memory alloys (SMAs) are the group of metallic materials that exhibit a shape-memory effect (SME). The shape-memory effect is the ability to return to a previously defined shape through an appropriate thermal procedure after being severely deformed, and is a consequence of a crystallographic reversible, thermoelastic martensitic transformation (TMT). In martensitic transformations, there exists a parent, high-temperature austenite crystallographic phase having higher symmetry. As the temperature lowers, the crystallographic structure changes to martensite, a phase with lower symmetry. It is possible for multiple variants or orientations of the martensite phase to be present in the same material.
[0004] Phase transformations between austenite and martensite exhibit a hysteresis and can be activated by either temperature or stress. Fig. 1 and Fig. 2 schematically illustrate the forward and reverse phase transformations in the strain-temperature (ε-T) plane and in the stress-strain (σ-ε) plane, respectively. [0005] Specifically, transformation through a thermocycle is illustrated in Fig. 1, where Ms (martensite start temperature) is the temperature at which martensite formation begins, Mf (martensite finish temperature) is that at which martensite formation terminates, As (austenite start temperature) is that at which the reverse transformation begins, and Af (austenite finish temperature) is that at which the reverse transformation terminates. When a SMA is heated above As, the martensite variants change to reproduce the shape of the parent phase. [0006] Fig. 2 corresponds to the case when an exemplary SMA is deformed at a constant temperature. This temperature is preferably in the range between Af and Md where Af is the previously defined austenite finish temperature, and Md marks the maximum temperature at which martensite can be induced by an applied stress without substantially plastically deforming the austenite phase. With an increase in stress level (analogous to a decrease in temperature in the previous case), the martensite phase starts to form in the material. The line from point A to point B represents the elastic deformation of a SMA. After point B, the strain or deformation is no longer proportional to the applied stress, and it is in the region between point B and point C that the stress-induced transformation of the austenitic phase to the martensitic phase begins to occur. There also can be an intermediate phase, called the rhombohedral phase (or more commonly, the "R- Phase"), depending upon the composition and the thermomechanical history of the alloy. At point C moving toward point D, the material enters a region of relatively constant stress with significant deformation or strain. This constant stress region is known as the loading plateau, and it is in this plateau region C-D that the transformation from austenite to martensite occurs.
[0007] At point D the transformation to the martensitic phase due to the application of stress to the specimen is substantially complete. Beyond point D the martensitic phase begins to deform, elastically at first, but, beyond point E, the deformation is plastic.
[0008] When the stress applied to the superelastic metal is removed, the material behavior follows the curve from point E to point F. Within the E to F region, elastic recovery occurs. At point F in the recovery process, the metal begins to transform from the metastable, martensitic phase back to the more stable austenitic phase.
[0009] In the region from point G to point H, which is also an essentially constant or plateau stress region, the phase transformation from martensite back to austenite takes place. This constant stress region G-H is known as the unloading plateau. The line from point I to the starting point A represents the elastic recovery of the metal to its original shape.
[0010] The ability to incur significant strain under an applied stress and to recover from the deformation upon removal of the load is commonly referred to as "superelasticity" and sometimes "pseudoelasticity." In an ideal system, superelastic behavior is characterized by regions of nearly constant stress upon loading and unloading, identified above as loading plateau stress C-D and unloading plateau stress G-H.
[0011] Numerous alloys having shape memory effect and superelasticity are known, such as silver-cadmium (Ag-Cd), gold-cadmium (Au-Cd), gold-copper- zinc (Au-Cu-Zn), copper-aluminum-nickel (Cu-Al-Ni), copper-gold- zinc (Cu-Au- Zn), copper-zinc (Cu-Zn), copper-zinc-aluminum (Cu-Zn-Al), copper-zinc-tin (Cu-Zn-Sn), copper-zinc-xenon (Cu-Zn-Xe), iron beryllium (Fe3Be), iron platinum (Fe3Pt), indium-thallium (In-Tl), iron-manganese (Fe-Mn), nickel-aluminum (Ni- Al), copper based alloys, as well as Ni-Ti (nickel-titanium) based alloys. Moreover, equiatomic or near-equiatomic nickel-titanium alloys (i.e., Nitinol) are very important for practical uses owing to their physical, mechanical and chemical properties, performance specifications, corrosion resistance and SME. In particular, Ti-Ni alloys can exhibit 50-60% elongation and have a tensile strength up to 1000 MPa. Upon heat treatment, Ti-Ni transforms from a ductile martensite phase with B 19' structure to a stiff er austenite phase of B2 structure. When cooled, Ti-Ni shifts in structure from B2 to B 19'. In bulk equiatomic Ti-Ni, Ms is approximately within the range of 60°C-65°C, and As is approximately 950C-IOO0C. These transformation temperatures, however, can be significantly lower for thin films and are highly dependent on composition and residual - A-
stresses. The martensitic transformations depend on the chemical composition of the alloy. Thus, when Nitinol is alloyed with other metals, cooling of the material can provide transformation of B2 structure to either B 19 structure or to the so- called R-phase, and then to the B 19' structure.
[0012] SMAs may be practically used for actuators, pipe couplings, switches or the like by taking advantages of their shape memory properties. Products that rely on the superelasticity of the SMAs include, but are not limited to, antennas, eye glass frames, wires of brassieres, orthodontic archwires, etc. Various proposals have also been made to employ SMAs in the medical field. For example, U.S. Pat. No. 3,620,212 to Fannon et al. proposes the use of an SMA intrauterine contraceptive device, U.S. Pat. No. 3,786,806 to Johnson et al. proposes the use of an SMA bone plate, U.S. Pat. No. 3,890,977 to Wilson proposes the use of an SMA element to bend a catheter or cannula, etc. In this connection, the functional capabilities of nickel-titanium alloys are especially important in medicine because their biochemical properties best match the mechanical behavior and properties of human living tissues. Various nickel-titanium alloys can also be used in guide wires, cardiac pacing leads, sutures, prosthetic implants, such as stents, intraluminal filters, retrieval baskets, aneurysm clips, bone plates and screws, femoral fixation devices, intramedullary nails and pins, and joints for ankles, elbows, fingers, knees, hips, shoulders and wrists. Such nickel-titanium alloys are described in, for example, U.S. Pat. Appl. Pub. Nos. 2001/0001317 to Duerig et al., 2004/0249447 and 2006/0086440 to Boylan et al., 2004/0143317 to Stinson, 2004/0236409 to Pelton et al, 2004/220608 to Wayne et al, 2005/209683 to YAMAUCHI, U.S. Pat. Nos. 5,951,793 to Mitose et al, 6,312,455 to Duerig et al, 6,306,141 to Jervis, 6,676,700 to Jacobs et al, 6,926,733 to Stinson, 6,776,795 to Pelton et al, 6,855,161 to Boylan et al.).
[0013] Although nickel-titanium alloys are useful and valuable to the medical field, one of the disadvantages of the medical implants made of the known SMAs is the fact that they are not sufficiently radiopaque, as compared to, for example, devices made of medical stainless steel. [0014] The radiopacity of medical implants can be improved in several ways. For example, virtually regardless of the energy and wavelength of incident x-rays, material having a high mass per unit of illuminated area (material density) is radiopaque; indeed, the radiopacity of high mass constructions is generally higher than that of low mass constructions. However, the extensive use in medical practice of small-size articles made from materials having SME and superelasticity imposes limits on the utilization of high mass constructions. [0015] Radiopacity can also be improved through coating processes such as sputtering, plating, or co-drawing high radiopacity metals onto the medical device. These processes, however, may create complications such as material compatibility, galvanic corrosion, coating adhesion or delamination, biocompatibility, etc.
[0016] Radiopacity can also be improved by alloy addition. A challenge for medical device applications is the preparation of a suitably radiopaque Ti-Ni alloy that also displays superelastic behavior around body temperature. It would be advantageous to develop a radiopaque nickel-titanium alloy that provides a substantial improvement in radiopacity compared to binary Ti-Ni alloys without a loss in superelastic properties.
SUMMARY OF THE INVENTION
[0017] Described herein is a radiopaque nickel-titanium alloy that may provide increased radiopacity compared to binary Ti-Ni alloys. The radiopaque alloy preferably displays superelastic behavior and shape memory properties suitable for medical device applications in the human body. Also disclosed herein is a medical device comprising the radiopaque nickel-titanium alloy. [0018] According to one embodiment, the alloy comprises at least one radiopaque alloying element to provide a desired radiopacity of the alloy. The alloy further comprises at least one additional alloying element to maintain the superelasticity properties of the alloy within a desired superelasticity temperature interval. The alloy may also comprise at least one further alloying element to provide instability of the alloy to a martensitic transformation in a predetermined instability temperature interval.
[0019] According to another embodiment, the alloy includes titanium at a concentration of from about 48 to about 52 atomic percent, and at least one radiopaque alloying element selected from the group consisting of palladium, platinum and gold, where palladium is at a concentration of from about 15 to about 35 atomic percent, and platinum and gold are at a concentration of from about 10 to about 35 atomic percent. The alloy also includes at least one additional alloying element selected from the group consisting of iron and cobalt at a concentration of from about 0.5 to about 8 atomic percent, and nickel as a balance.
[0020] According to another embodiment, the alloy includes titanium at a concentration of from about 48 to about 52 atomic percent, and at least one radiopaque alloying element selected from the group consisting of palladium, platinum and gold, where palladium is at a concentration of from about 15 to about 35 atomic percent, and platinum and gold are at a concentration of from about 10 to about 35 atomic percent. The alloy also includes at least one additional alloying element selected from selected from the group consisting of aluminum, chromium and zirconium, where aluminum and chromium are at a concentration of from over 0 to 2 atomic percent and zirconium is at a concentration of from over 0 to about 6 atomic percent, and the balance of the alloy is nickel.
[0021] According to another embodiment, the alloy consists essentially of titanium at a concentration of from about 48 to about 52 atomic percent; at least one radiopaque alloying element selected from the group consisting of palladium, platinum and gold, where palladium is at a concentration of from about 15 to about 35 atomic percent, and platinum and gold are at a concentration of from about 10 to about 35 atomic percent; at least one additional alloying element selected from the group consisting of iron and cobalt at a concentration of from about 0.5 to about 8 atomic percent; at least one further alloying element selected from the group consisting of aluminum, chromium and zirconium, where aluminum and chromium are at a concentration of from over 0 to about 2 atomic percent, and zirconium is at a concentration of from over 0 to about 6 atomic percent; and nickel and inevitable impurities as a balance. [0022] According to another embodiment, the alloy includes at least one radiopaque alloying element at a concentration of from about 10 at.% to about 20 at.%, where the radiopaque alloying element is selected from the group consisting of gold, platinum, and palladium. The nickel-titanium alloy also includes at least one additional alloying element selected from the group consisting of aluminum, chromium, cobalt, iron, and zirconium, where the additional alloying element has a concentration of from about 0.5 at.% to about 4 at.%. The alloy includes titanium at a concentration of from about 48 at.% to about 52 at.% and the balance of the alloy is nickel. Preferably, the alloy has a radi opacity greater than that of a binary nickel-titanium alloy and exhibits a recoverable strain of at least about 2% upon removal of a deforming stress at about body temperature. [0023] According to another embodiment, the alloy includes a radiopaque constituent comprising one or more radiopaque elements selected from the group consisting of gold, platinum, and palladium, where the radiopaque constituent has a concentration of from about 10 at. % to about 35 at. %. The alloy also includes an additional constituent comprising one or more additional alloying elements selected from the group consisting of aluminum, chromium, cobalt, iron, and zirconium, where the additional constituent has a concentration of from about 0.5 at.% to about 13 at.%. The alloy includes titanium at a concentration of from about 48 at.% to about 52 at.%, and the balance of the alloy is nickel. Preferably, the alloy has a radi opacity greater than that of a binary nickel -titanium alloy and exhibits a recoverable strain of at least about 2% upon removal of a deforming stress at about body temperature.
[0024] According to one embodiment, the medical device has at least one component comprising a radiopaque alloy having shape memory and superelastic properties, where the radiopaque alloy comprises titanium at a concentration of from about 48 to about 52 atomic percent, at least one element selected from the group consisting of palladium, platinum and gold, where palladium is at a concentration of from about 15 to about 35 atomic percent, and platinum and gold are at a concentration of from about 10 to about 35 atomic percent, and at least one element selected from the group consisting of iron and cobalt at a concentration of from about 0.5 to about 8 atomic percent, with the balance nickel. [0025] According to another embodiment, the medical device has at least one component comprising a radiopaque alloy having shape memory and superelastic properties, where the radiopaque alloy comprises titanium at a concentration of from about 48 to about 52 atomic percent, at least one element selected from the group consisting of palladium, platinum and gold, where palladium is at a concentration of from about 15 to about 35 atomic percent, and platinum and gold are at a concentration of from about 10 to about 35 atomic percent, and at least one element selected from selected from the group consisting of aluminum, chromium and zirconium, where aluminum and chromium are at a concentration of from over 0 to 2 atomic percent and zirconium is at a concentration of from over 0 to about 6 atomic percent, with the balance nickel. [0026] According to another embodiment, the medical device has at least one component comprising a radiopaque alloy having shape memory and superelastic properties, where the radiopaque alloy consists essentially of titanium at a concentration of from about 48 to about 52 atomic percent, at least one element selected from the group consisting of palladium, platinum and gold, where palladium is at a concentration of from about 15 to about 35 atomic percent, and platinum and gold are at a concentration of from about 10 to about 35 atomic percent, at least one element selected from the group consisting of iron and cobalt at a concentration of from about 0.5 to about 8 atomic percent, and at least one element selected from selected from the group consisting of aluminum, chromium and zirconium, where aluminum and chromium are at a concentration of from over 0 to about 2 atomic percent and zirconium is at a concentration of from over 0 to about 6 atomic percent, with nickel and inevitable impurities as the balance.According to another embodiment, the medical device comprises at least one component including a radiopaque nickel-titanium alloy, and the nickel- titanium alloy includes at least one radiopaque alloying element at a concentration of from about 10 at.% to about 20 at.%, where the radiopaque alloying element is selected from the group consisting of gold, platinum, and palladium, and at least one additional alloying element selected from the group consisting of aluminum, chromium, cobalt, iron, and zirconium, where the additional alloying element has a concentration of from about 0.5 at.% to about 4 at.%. The alloy includes titanium at a concentration of from about 48 at.% to about 52 at.%; and the balance is titanium. Preferably, the alloy has a radi opacity greater than that of a binary nickel-titanium alloy and a recoverable strain of at least about 2% upon removal of a deforming stress at about body temperature. [0027] According to another embodiment, the medical device comprises at least one component including a radiopaque nickel-titanium alloy, where the nickel-titanium alloy includes a radiopaque constituent comprising one or more radiopaque elements selected from the group consisting of gold, platinum, and palladium, where the radiopaque constituent has a concentration of from about 10 at. % to about 35 at. %. The alloy also includes an additional constituent comprising one or more additional alloying elements selected from the group consisting of aluminum, chromium, cobalt, iron, and zirconium, where the additional constituent has a concentration of from about 0.5 at.% to about 13 at.%. The alloy includes titanium at a concentration of from about 48 at.% to about 52 at.% and the balance of the alloy is nickel. Preferably, the alloy has a radiopacity greater than that of a binary nickel-titanium alloy and a recoverable strain of at least about 2% upon removal of a deforming stress at about body temperature.
BRIEF DESCRIPTION OF THE DRAWINGS
[0028] In order to understand the invention and to see how it may be carried out in practice, preferred embodiments will now be described, by way of non- limiting examples only, with reference to the accompanying drawings, in which: [0029] Fig. 1 schematically illustrates a complete thermodynamic cycle of a shape memory alloy in the strain-temperature (ε-T) plane; [0030] Fig. 2 schematically illustrates a complete thermodynamic cycle of a shape memory alloy in the stress-strain (σ-ε) plane;
[0031] Figs. 3A-3C are exemplary phase diagrams of martensitic transformations for Ti50 oNi5O 0-xPdx, Ti50 oNi5O o-xPtx and Ti50 oNi5O 0-xAux compositions, respectively;
[0032] Figs. 4A and 4B are exemplary phase diagrams of martensitic transformations for Ti50 oNi5O 0-xFex, and Ti50 0Ni50 o-xCox compositions, respectively;
[0033] Fig. 5A illustrates an exemplary phase diagram of martensitic transformation for Ti50 o-xNi5O OA1X compositions;
[0034] Fig. 5B illustrates an exemplary phase diagram of martensitic transformation for Ti50 o-xNi5o 0Zrx compositions;
[0035] Fig. 6A and 6B are exemplary phase diagrams of martensitic transformations in alloys Ti5o-xNi5O+x subjected to different processing;
[0036] Fig. 7 illustrates the comparative contrast of x-ray pictures of exemplary wire samples;
[0037] Fig. 8 illustrates the dependence of the relative contrast of the x-ray pictures shown in Fig. 7 on the amount of the radiopaque alloying elements;
[0038] Figs. 9-14 illustrate stress-strain plots for measurements at various temperatures of exemplary alloys prepared in accordance with the present disclosure; and
[0039] Fig. 15 illustrates an exemplary medical device including the radiopaque alloy according to one embodiment.
DETAILED DESCRIPTION OF EXEMPLARY EMBODIMENTS
[0040] The selection of alloying elements for a radiopaque Ti-Ni alloy composition was influenced by the desire to retain the biocompatibility properties of the Ti-Ni alloys, improve the radi opacity of the Ti-Ni alloys, obtain superelastic behavior from the Ti-Ni alloys, and shift the phase transformation temperatures (e.g., Af) to a range appropriate for biomedical use of a device (or article) made of such alloys.
[0041] For example, small amounts of Pd and/or Au and/or Pt may not provide the desired level of the radiopacity of the alloy, whereas excessively high concentrations may deteriorate the superelastic properties and undesirably increase the phase transformation temperatures of the alloy. Accordingly, the alloy may include one or more additional alloying elements (e.g., Al, Zr, Cr, Fe, and/or Co) to aid in reducing the phase transformation temperatures to values suitable for an insertable or implantable medical device.
[0042] The alloys described herein may be used for the production of medical devices that exhibit both radiopacity and superelastic effects, since the alloys preferably contain at least one radiopaque element and at least one additional alloying element that promotes the retention of superelastic properties in a temperature range suitable for use in the human body. [0043] Thus, according to one embodiment, described herein is a shape memory alloy based on titanium nickelide and having radiopaque and superelastic properties, including: at least one radiopaque element replacing a part of nickel and/or titanium in such amount so as to provide a desired radiopacity of the alloy without causing the destruction of a structure of high-temperature B2-phase; at least one alloying element replacing a part of nickel and/or titanium in such amount so as to maintain the superelasticity properties of the alloy within a desired superelasticity temperature interval; and at least one alloying element replacing a part of nickel and/or titanium in such amount so as to provide instability of the alloy to a martensitic transformation in a predetermined instability temperature interval.
[0044] Preferably, each alloying element is an electronic analog of titanium or nickel. Further, the alloying elements may form a continuous series of solid substitution solutions. The influence of the alloying elements on the electronic subsystem of the crystalline lattice of titanium nickelide preferably results in (i) a desired variation of the temperatures of martensitic transformation, and (ii) maximal extension of the temperature interval in which the alloy is unstable to martensitic transformation.
[0045] Applicants believe that the radi opacity of the Ti-Ni alloy can be significantly improved and the biocompatibility properties of the material can be retained when palladium (Pd), platinum (Pt) and/or gold (Au) are used as main ternary alloying elements in amounts greater than about 15 atomic percent for Pd, and greater than about 10 atomic percent for Pt and Au. Indeed, as Ni atoms in TiNi are substituted with one or a combination of these elements, secondary phases may not be formed in the quasi-binary section TiNi-TiMe (where, Me is an element selected from Pd, Pt, Au). Without wishing to be bound by theory, Applicants believe that his phenomenon may be explained by the formation of intermetallic compounds having the composition ratio Ti50 oMe5O 0 (at.%) with B2 superstructure and CsCl type order, i.e., with an atomic structure similar to TiNi, when titanium is alloyed with Pd, Pt, or Au. Therefore, as the Me concentration in Ti50 oNi5O o-χMex alloys is increased along the quasi-binary sections TiNi-TiMe (where Me is selected from Pd, Pt, Au), the structure of the high-temperature B2 phase may be retained. Retaining the B2-phase in all these quasi-binary sections (TiNi-TiPd, TiNi-TiPt, TiNi-TiAu) may make it possible to retain thermoelastic martensitic transformations in Ti500Ni50 o-χMex alloys and, consequently, to exhibit shape memory and superelasticity effects.
[0046] Referring to Figs. 3A through 3C, exemplary phase diagrams of martensitic transformation temperatures for Ti50 oNiso o-xPdx, Ti50 0Ni5o o-χPtx and Ti500Ni50 o-χAux compositions are shown respectively. As illustrated in Fig. 3A, when when the concentration (x) of Pd increases from 0 to about 7 atomic percent, the martensite start temperature Ms and martens ite finish temperature Mfof the Ti500Ni50 o-xPdx alloy both decrease. The further addition of Pd increases the phase transformation temperatures Ms and Mf. Thus, at about 14 atomic percent Pd, the transformation temperatures Ms and Mf correspond to those of binary Ti50 0Ni500 alloy. The transformation temperatures continue to increase at higher concentrations of Pd. [0047] As illustrated in Fig. 3B, the temperatures of martensitic transformation Ms and Mf slightly decrease when the concentration (x) of Pd increases from 0 to about 3 atomic percent. In the range of about 3 to about 9 atomic percent, the transformation temperatures do not substantially change their values. However, the further addition of Pd beyond about 9 atomic percent results in an increase of Ms and Mf.
[0048] The phase diagram of martensitic transformation for Ti50 oNi5O o-χAux shows similar behavior (see Fig. 3C). The transformation temperatures Ms and Mf slightly decrease when the concentration (x) of Au increases from 0 to about 3 atomic percent. When x increases beyond this range, the phase transformation temperatures increase, first gradually and then more rapidly beyond a concentration of about 20 at.% Au.
[0049] As can be understood from Figs. 3A through 3C, although the alloying of TiNi with Pd, Pt or Au atoms results in higher radiopacity of the alloy in comparison with binary TiNi, the addition of Pd, Pt or Au at the amounts of greater than about 10 to about 15 atomic percent may increase the phase transformation temperatures of the alloy. An increase in the martensitic transformation temperatures (Ms and Mf) upon cooling is generally linked to an increase in the austenitic transformation temperatures (As and Af) upon heating. [0050] An increase in the phase transformation temperatures of a shape memory alloy can be in conflict with the intended use of a device made of this alloy. In particular, when the alloy is intended for use in a medical device inserted or implanted within a living body, it may be advantageous for Af to be less than or equal to the temperature of the living body (e.g., 370C). For example, self- expanding stents are generally compressed to a reduced diameter and restrained within a tubular sheath for delivery within a body vessel; once in place at a treatment site, they are deployed superelastically to an expanded configuration so as to contact the vessel wall. During superelastic deployment, stress applied to the stent is released (e.g., the sheath is retracted) so that martensite present in the stent during delivery may transform to austenite and the stent may recover a previous state (e.g., the expanded configuration). If Af is above body temperature, however, then the stent may not fully deploy automatically upon retraction of the sheath. Accordingly, it is preferably that the Ti-Ni alloy has an austenite finish temperature Af which is less than or equal to human body temperature so that release of an applied stress is sufficient to trigger the transformation to the austenitic phase. It may also be advantageous for Ms to be less than room temperature (e.g., less than about 2O0C).
[0051] Therefore, one or more quaternary alloying elements may be added to the ternary alloy compositions Ti500Ni500-xMex (where Me is selected from Pd, Pt, Au) to reduce the transformation temperatures to the desired temperature range. Preferably, the additional alloying elements do not deteriorate the radiopacity of the alloy. The radiopacity of the alloy aids in positioning the device in the desired location in the body passageway during delivery and deployment. It is also preferred that the quaternary alloying elements do not detrimentally affect the superelastic and/or mechanical properties of the Ti50 0Ni50 O-XMex alloy. [0052] According to one embodiment, such a quaternary alloying element can be either iron (Fe) or cobalt (Co). Specifically, it is known that when titanium is alloyed with iron or cobalt at an equiatomic ratio (i.e., Ti500Fe50 0 and Ti50 0Co500 (at.%)), intermetallic compounds with the B2 superstructure may be formed, i.e., their structure is similar to that of the high-temperature B2-phase of TiNi. Hence, TiNi alloyed with the atoms of Fe and/or Co instead of Ni may allow the B2-phase structure of the material to be retained.
[0053] Referring to Figs. 4A and 4B, exemplary phase diagrams of martensitic transformation for Ti500Ni500-xFex, and Ti500Ni50 0-xCox compositions are shown, respectively. Alloying of TiNi with atoms of Fe and Co may cause a decrease in the martensitic transformation temperatures. As illustrated in Fig. 4A, the martensite finish temperature Mf of Ti500Ni500-xFex drastically decreases by about 2000C when x changes from 0 to about 3 atomic percent. The martensite start temperature Ms of the Ti500Ni50 0-xFex alloy behaves in a similar manner at increasing iron concentrations. Likewise, as illustrated in Fig. 4B, the temperature of martensitic transformation Mf of Ti50 0Ni500-xCox drastically decreases by about 2000C when x changes from about 0 to 7 atomic percent. The martensite start temperature Ms of the Ti50 oNi50 0-xCox alloy decreases by about 75°C over the same concentration range.
[0054] Moreover, Applicants believe that these alloying elements (Fe and Co, each one separately) may modify the sequence of martensitic transformation from B2→Bl9'm TiNi to B2→R→B19'in Ti500Ni50 0-xFex and/or Ti50 0Ni50 0-xCox, which may have a favorable effect on the exhibition of the superelasticity effect. [0055] Applicants also believe that when atoms of Ni in TiNi are substituted with both the radiopaque alloying elements Pd, Pt and/or Au together with alloying elements Fe and/or Co, the alloying elements of these two groups independently influence the temperature of martensitic transformation. For example, atoms of Pd introduced instead of atoms of Ni in TiNi may increase the temperature of martensitic transformations in accordance with the diagram of martensitic transformations TiNi-TiPd, while atoms of Fe may decrease the temperature of martensitic transformations in accordance with the diagram of martensitic transformations TiNi-TiFe.
[0056] Hence, according to one embodiment of the present invention, the concept of producing a radiopaque NiTi-based alloy exhibiting superelastic behavior around body temperature, i.e., having an austenite finish temperature Af of less than or equal to 37°C, is as follows.
[0057] First, TiNi is preferably alloyed with one or more components selected from Pd, Pt and Au. The one or more components replace a part of nickel and/or titanium and may sufficiently increase the radiopacity without causing the destruction of the superstructure of the high-temperature B2-phase of TiNi. In order to significantly improve the radiopacity of the TiNiMeI alloy (when Mel is Pd), it is preferred that the amount of the alloying elements Mel exceeds 15 atomic percent. Even more preferably, the amount of the alloying element Mel exceeds 20 atomic percent when Mel is Pd. Likewise, the radiopacity of the TiNiMeI alloy (when Mel is selected from Pt and Au) can sufficiently be improved when the amount of the alloying elements Mel exceeds 10 atomic percent. Preferably, the amount of the alloying elements Mel exceeds 15 atomic percent when Mel is Pt.
[0058] Therefore, according to one embodiment of the present invention, the amount of the alloying elements Mel in the TiNiMeI alloy is in the range of about 15% to 35% (by atomic percent) when Mel is Pd, and in the range of about 10% to 35% (by atomic percent) when Mel is Pt and/or Au.
[0059] Preferably, the amount of Ti in the alloy is maintained in the range of about 48% to about 52% (by atomic percent), although other ranges are also possible. If the titanium concentration in the alloy is less than about 48 at. % or more than about 52 at. %), undesirable secondary phases may form. These secondary phases may not undergo martensitic transformations and may have a negative effect on the superelastic behavior of the alloy.
[0060] As described above, the adding of the alloying elements Mel may raise the phase transformation temperatures of the alloy. Therefore, in order to return the phase transformation temperatures to the desired temperature interval (e.g., Af to less than or equal to human body temperature) without detrimentally affecting the radiopacity, at least one component of Me2 selected from Fe and/or Co can be further added to the alloy by replacing a part of nickel and/or titanium. A preferred amount of Fe and/or Co in TiNiMelMe2 alloy can be in the range of about 0.5% to about 8% (by atomic percent).
[0061] According to another embodiment of the invention, in order to decrease the phase transformation temperatures, one or more components of Me3 selected from aluminum (Al) and chromium (Cr) can be further added to the TiNiMe lMe2 alloy by replacing a part of nickel and/or titanium. Moreover, adding Al and/or Cr may provide a wide temperature interval of instability of the intermetallic compound to the martensitic transformation. For example, adding Al and/or Cr may extend the temperature interval of instability to a range wider than 50 degrees. In this case, the instability temperature interval may be greater than the instability temperature interval of the equiatomic Ti-Ni alloy. [0062] Fig. 5A illustrates an exemplary phase diagram of martensitic transformation for Ti50 o-xNi5O OA1X compositions. When the concentration (x) of Al in the alloy increases from 0 to about 2 atomic percent, the martensite start temperature Ms decreases.
[0063] A preferred amount of Al and/or Cr in the TiNiMe lMe2Me3 alloy is less than about 2 at. %. Applicants believe that when the amount of Al or Cr exceeds 2 at. %, secondary phases may be formed in the alloy that may adversely affect the completeness of the phase transformations and, accordingly, may deteriorate the shape memory and superelastic properties of the material. [0064] According to a further embodiment, zirconium (Zr) can be added either to the TiNiMe lMe2 alloy or to the TiNiMe lMe2Me3 alloy by replacing a part of nickel and/or titanium. Specifically, Zr can be dissolved in the alloy in amounts much greater than Al and Cr. According to one embodiment, Zr can be dissolved in the amount of about 6 at. %, and preferably in the amount of 4 at. %. Preferably, the addition of zirconium does not lead to the formation of a secondary phase (in contrast to the effect expected when atoms of Al and Cr are added). Moreover, adding zirconium may also provide a wide temperature interval of instability of the Ti-Ni alloy to martensitic transformation. The expression "wide temperature range" herein refers to a temperature interval greater than 50 degrees. [0065] Fig. 5B illustrates exemplary phase diagrams of martensitic transformation for Ti500-XNi5O oZrx compositions. When the zirconium concentration (x) increases from 0 to about 4 atomic percent, the martensite start temperature Ms and finish temperature Mfboth decrease. The further addition of Zr increases the phase transformation temperatures Ms and Mf. At about 9 atomic percent zirconium, the transformation temperatures Ms and Mf correspond to those of binary Ti500Ni500 alloy. Beyond about 9 at. % Zr, the martensitic transformation temperatures further increase.
[0066] It should also be understood that variation of the phase transformation temperatures can be achieved by departing from the stoichiometric relationship between Ni and Ti in the Ti50 0Ni50 0 alloy. Fig. 6A shows an exemplary phase diagram of martensitic transformations in alloys Ti50-xNi50+x quenched from 10730K; and Fig. 6B shows an exemplary phase diagram of martensitic transformations in alloys Ti5o-xNi5o+x annealed at the temperature of 10730K (for 1 hour) and then cooled to room temperature. As can be seen, at nickel concentrations higher than about 50.0 at.%, the martensitic transformation temperatures of the TiNi alloy decrease.
[0067] Generally speaking, Applicants believe that the upward trend in martensitic transformation temperatures associated with additions of platinum, palladium, or gold at concentrations above about 10 at.% may be balanced by small additions of other alloying elements, such as iron, cobalt, aluminum, and/or zirconium.
[0068] Applicants also believe that adding boron (B) to a NiTi-based alloy can improve the ductility of the alloy, where boron plays a role of a plastificator. Thus, according to a further embodiment, boron may be further added to the NiTi-based alloys described herein by replacing a part of nickel and/or titanium. A preferred amount of B in the TiNi-based alloys can be in the range of about 0.05 at.% to about 0.2 at.% .
[0069] According to one preferred embodiment, the radiopaque nickel-titanium alloy includes: at least one radiopaque alloying element at a concentration of from about 10 at.% to about 20 at.%, where the radiopaque alloying element is selected from the group consisting of gold, platinum, and palladium; at least one additional alloying element selected from the group consisting of aluminum, chromium, cobalt, iron, and zirconium, where the additional alloying element has a concentration of from about 0.5 at.% to about 4 at.%; titanium at a concentration of from about 48 at. % to about 52 at.%; and nickel as the balance. According to one embodiment, the concentration of the additional alloying element may be in the range of from about 0.5 at.% to about 1.2 at.%. Preferably, the nickel has a concentration of from about 29 at.% to about 52 at.%
[0070] For example, the radiopaque nickel-titanium alloy may include gold at a concentration of about 20 at.%, iron at a concentration of about 0.5 at.%, and zirconium at a concentration of about 1 at.%. [0071] In another example, the radiopaque nickel-titanium alloy may include gold at a concentration of about 10 at.%, iron at a concentration of about 1.2 at.%, and zirconium at a concentration of about 1 at.%.
[0072] In another example, the radiopaque nickel-titanium alloy may include gold at a concentration of about 15 at.% and aluminum at a concentration of about 1.2 at.%.
[0073] In yet another example, the radiopaque nickel-titanium alloy may include gold at a concentration of about 15 at.%, and chromium at a concentration of about 1 at.%.
[0074] Alternatively, the radiopaque nickel-titanium alloy may include platinum at a concentration of about 15 at.%, iron at a concentration of about 4 at.%, and zirconium at a concentration of about 1 at.%.
[0075] According to another preferred embodiment, the radiopaque nickel- titanium alloy may comprise: a radiopaque constituent comprising one or more radiopaque elements selected from the group consisting of gold, platinum, and palladium, where the radiopaque constituent has a concentration of from about 10 at. % to about 35 at. %; an additional constituent comprising one or more additional alloying elements selected from the group consisting of aluminum, chromium, cobalt, iron, and zirconium, where the additional constituent has a concentration of from about 0.5 at.% to about 13 at.%; titanium at a concentration of from about 48 at.% to about 52 at.%; and the balance nickel, wherein the alloy has a radiopacity greater than that of a binary nickel-titanium alloy and a recoverable strain of at least about 2% upon removal of a deforming stress at about body temperature. Preferably, the concentration of the radiopaque constituent is from about 10 at.% to about 20 at.% and the concentration of the additional constituent is from about 1 at.% to about 5 at.%. It is also preferred that the nickel has a concentration of from about 29 at.% to about 52 at.%. [0076] For example, the radiopaque constituent may be gold at a concentration of about 20 at.%, and the additional constituent may include iron and zirconium, where the additional constituent has a concentration of about 1.5 at.%. [0077] In another example, the radiopaque constituent may be gold at a concentration of about 10 at.%, and the additional constituent may include iron and zirconium, where the additional constituent has a concentration of about 2.2 at.%.
[0078] In another example, the radiopaque constituent may be gold at a concentration of about 15 at.%, and the additional constituent may include one of aluminum and chromium, where the additional constituent has a concentration in the range of from about 1.0 at.% to about 1.2 at.%.
[0079] In yet another example, the radiopaque constituent may be platinum at a concentration of about 15 at.%, and the additional constituent may include iron and zirconium, where the additional constituent has a concentration of about 5 at.%.
[0080] Phase transformation temperatures (e.g., martensite start temperature
M5) of a quaternary or quintary nickel-titanium alloy can be estimated on the basis of the known effect of each individual alloying element on the phase transformation temperatures of the binary TiNi system, assuming that the individual effects are cumulative in a multicomponent system, as described below.
[0081] Example 1.1
[0082] To broadly estimate the martensite start temperature Ms of a quaternary or quintary Ti-Ni alloy of interest, such as Ti49 5Ni222Au25 0Fe23Zrj 0, a change in the martensite start temperature Ms relative to the binary TiNi system can be derived for each alloying element (e.g., Au, Fe, and Zr) at the appropriate concentration using the data provided in Figs. 3 A to 5B, and then the respective changes may be summed as discussed in this and the related examples below.
[0083] For example, the martensite start temperature Ms of the alloy
Ti49 5Ni222Au25 0Fe23Zη 0 can be estimated on the basis of the corresponding temperature increments AT=(Ms(Ti500Ni50 o-χMex) - M5(Ti50 0Ni50 0)} for variations of Ts of ternary compositions of the Ti-Ni alloy alloyed with a ternary element
(Me). [0084] In calculations, the value of M5(Ti50 0Ni50 0)~+55°C for martensite start temperature of Ti50 ONi5O 0 was considered. According to the martensitic transformation diagram (shown in Fig. 3C), adding a radiopaque alloying element Au in the amount of 25 at.% by replacing 25 at.% of Ni increases M3 from about 55°C for the binary TiNi alloy to about 14O0C for the Ti50Ni25Au25 alloy. Accordingly, ΔTAu * { M5(Ti50Ni25Au25) - M5(TiNi)) « (1400C - 60°C) « 8O0C. [0085] Further, in order to decrease Ms, the alloying element Fe can be added. According to the martensitic transformation diagram shown in Fig. 4A, adding the alloying element Fe in the amount of 2.3 at.% by replacing 2.3 at.% Ni decreases M5 from about +550C for the binary TiNi alloy to about -750C for the Ti50Ni47 7Fe2 3 alloy. Accordingly, ΔTFe * (M5(Ti50Ni47 7Fe23) - M5(TiNi)) » (-75°C - 55°C) « -130°C.
[0086] Applicants believe that adding Fe in the amount of 2.3 at.% to Ti50Ni25Au25 by replacing 2.3 at.% of Ni can decrease M5 of the Ti50Ni25Au25 alloy by about the same value ΔTFe ~ -130° C. Thus, the value of M5(Ti50Ni22 7Au25 0Fe2 3) may be estimated to be approximately equal to (Ms(Ti50Ni25Au25) + ΔTFe) ~ (140°C -130°C ~ 10βC). One can also calculate a value ΔTAu + ΔTFe » 80°C +( -1300C) =-50°C which represents the estimated combined effect of 25 at.% Au and 2.3 at.% Fe on the binary TiNi system. Accordingly, M5(Ti50Ni22 7Au25 0Fe2 3) « M5(TiNi) + ΔTAu + ΔTFe « 55°C + (-500C) « +5°C. Taking into account the hysteresis of the phase transformation temperatures (see Fig. 1) and assuming a temperature differential T1 of approximately 300C to 35°C, Af may be estimated to be « 350C -400C. [0087] Finally, the transformation temperatures can be further reduced by adding the alloying element Zr in the amount of 1.0 at. % by replacing 0.5 at. % of Ti and 0.5 at. % of Ni. According to the martensitic transformation diagram shown in Fig. 5B, adding the alloying element Zr in the amount of 1.0 at. % by replacing 0.5 at. % of Ti and 0.5 at. % Ni decreases M5 to the temperature M5(Ti49 5Ni49 5Zr] 0) ~45°C from an assumed binary value of 55°C. Accordingly, ΔTZr « (M5(Ti49 5Ni49 5Zr1 „) - M5(TiNi)) ~ (450C - 55°C) * -100C. [0088] Hence, the temperature Ms of the multi-component Ti49 5Ni222Au25 0Fe23Zr1 0 alloy can be estimated as Ms ~ (M3(TiNi) + ΔTAu + ΔTFe + ΔTZr} ~ {55°C + 80°C + (-130°C) + (-10°C)} «-5°C, where M5 of TiNi is assumed to be 600C. Taking into account the hysteresis of the phase transformation temperatures as above, the temperature of the onset of the reverse martensitic transformation in such an alloy can be estimated as Af»20oC-30oC. [0089] A concentration C of the balance element (e.g., Ni) in atomic percent is determined from the formula CN , = (100-CTl-CAu-CFe-CZr) at. %. [0090] Example 1.2
[0091] The same procedure as described in Example 1.1 may be employed to estimate the transformation temperatures for a Ti48 7Ni35 0Au15 0Al1 3 alloy. [0092] Referring to Fig. 3C, alloying a binary TiNi alloy with a radiopaque alloying element Au in the amount of 15 at.% by replacing 15 at.% of nickel increases M5 from about 55 "C for the binary TiNi system to approximately 1000C for the Ti50Ni35Au15 alloy. Thus, M5(Ti50Ni35Au15) « 100°C and ΔTAu « (100°C - 55°C) = 45°C.
[0093] Further, in order to decrease M5 and facilitate superelastic properties, for example, such an alloying element as Al can be used. Referring to the martensitic transformation diagram for Ti500-xNi50 OA1X of Fig. 5A, adding Al in the amount of 1.3 at.% by replacing 1.3 at.% of Ti decreases M5 from about 74°C to approximately -37°C for the Ti48 7Ni50 OA1] 3 alloy. Thus, M5(Ti48 7Ni50 0Al1 3) « -37°C and ΔTAI « (-37T - 74°C) « -111°C.
[0094] Hence, the temperature M5 of the multi-component Ti48 7Ni35 0Au15 0Al1 3 alloy alloy can be estimated as M5 ~ (M5(TiNi) + ΔTAu + AT A1) * {55°C + 45°C + (-11 IT)} » -11°C, where M8 of TiNi is assumed to be 55°C. Taking into account the hysteresis of the phase transformation temperatures as above, the temperature of the onset of the reverse martensitic transformation in such an alloy can be estimated as Af« 19°C-24°C. [0095] Example 1.3
[0096] The same procedure as described in Example 1.2 may be employed to estimate the transformation temperatures for a Ti48 7Ni35 oAu15 QCr1 0 alloy. [0097] In order to fabricate a multi-component alloy based on titanium nickelide and having desired radiopaque property and desired martensitic transformation temperature, first, a binary TiNi alloy can be alloyed similar to Example 2 with a radiopaque alloying element Au in the amount of 15 at.% by replacing 15 at.% of nickel. As described in the previous example, this alloying increases Ms from about 55°C to the temperature M5(Ti50Ni35Au15) -100 °C (i.e., by ΔTAu « 45°C).
[0098] According to this example, in order to decrease Ms, an alloying element such as Cr can be used. For instance, it is known that adding Cr in the amount of 1.0 at.% by replacing 1.0 at.% of Ni decreases M5 to the temperature M5(Ti50 C)Ni49 o 0Cr1 0) « -8O0C (i.e., by ΔTCr ~ -135°C, assuming that the M5 of TiNi is 55°C). Further assuming that adding Cr in the amount of 1.0 at.% to a ternary alloy Ti50 0Ni35 0Au15 0 by replacing 1.0 at.% of Ni will decrease M5 by about the same value (ΔTCr « -135°C) as in the case of addition to the binary alloy Ti50Ni50, then the temperature M5(Ti50 0Ni34 0Au15 0Cr1 0) can be estimated to be about -35°C. Accordingly, the temperature of the onset of the reverse martensitic transformation for Ti48 7Ni35 0Au15 0Cri 0 can approximately be estimated as Af ~ -5°C to 0°C.
Table 1. Preferred Composition Ranges for the Ti-Ni Alloys
Figure imgf000024_0001
Figure imgf000025_0001
[0099] Suitable composition ranges for the radiopaque nickel-titanium alloy are presented in Table 1. The alloys described hereinabove can be fabricated by melting Ti, Ni mixed with alloying elements according to the compositions suggested above. According to one embodiment, the melting of the composition can be carried out by mixing all the alloying elements together and then applying elevated temperatures to the mixture. According to another embodiment, the melting of the composition can be carried out by first mixing and melting only base alloying elements with a consequent cooling of this mixture, and then adding one or more secondary alloying elements and remelting the mixture one or more times again.
[00100] The mixture can, for example, be heated and molten in an induction furnace, arc furnace or other suitable oven in a protective atmosphere. The mixture may be molten in a purified helium or argon atmosphere. For instance, the melting can be carried out at a constant temperature, e.g. at a temperature within the temperature interval of about 12000C to 1400°C. Alternatively, the melting can be carried out by elevating the temperature at a rate of, for example, 5°C per minute to 50°C per minute from about room temperature to a temperature in the range of about 1200°C to 1400°C. Thereafter, the melt can be poured to a cooled mold, e.g. to a water-cooled mold made of brass, copper or other suitable material. When desired, the ingot can then be remelted for consistency. After cooling, the solidified body (ingot) can be taken from the mold and hot- worked into a bar, a wire or a slab. After melting and cooling, the ingot can be annealed by, for example, keeping the ingot at a temperature in the range of from about 800°C to 1100°C for a time period between 10 minutes and 2 hours. [00101] Embodiments of the fabrication method described above were employed to produce 29 alloy compositions in the form of ingots or buttons. Three of the 29 alloys were binary Ti-Ni compositions. Seven of the 29 alloys included one additional alloying element (Pd, Pt, Au, or Cu) beyond titanium and nickel. Nine of the 29 alloys included two additional alloying elements (Au + Al or Au + Cr). Ten of the 29 alloys included three additional alloying elements (Pt + Fe + Zr or Au + Fe + Zr).
[00102] Referring to Table 2, alloys designated as numbers 4, 13, 14, 15, and 16 were selected from all of the melted compositions for further investigation. Alloys designated as numbers 4/2, 4/3, and 15/2 are remelts of alloys 14 and 15, respectively. As will be discussed below, substantial recoverable strains were obtained from stress-strain tests of each of these alloys. Preferably, the alloy has a recoverable strain of at least about 2% upon removal of a deforming stress at about body temperature. It is preferred that the recoverable strain is at least about 5%. It is believed that the selected alloys may have sufficient ductility to undergo further mechanical working into forms such as strip, wire or plate. [00103] Bars of specified dimensions were prepared from samples 4, 13, 14,
15 and 16 by an electroerosion cutting technique for the purpose of conducting mechanical tests on the specimens. Specifically, for measurements of stress versus strain (i.e., to obtain σ(ε) curves), bars having a rectangular cross-section of 1.2 mm by 1.2 mm and a length of 26.0 mm were fabricated from the ingots. The sides of the bars were polished, and the bar samples were tested using a machine equipped with a thermal chamber in order to evaluate the superelastic behavior of the specimens at different temperatures. The mechanical tests were carried out by applying torsional stresses to the samples.
[00104] Specifically, an installation of a contrary tensional pendulum was utilized to perform the tests. Each sample was placed vertically in the installation. The bottom end of the sample was clamped by a split terminal and fixed. The top end of the sample was also clamped by the split terminal, and to this end a gradually increasing external tension in the form of a torsional stress was applied. Thus, a torsional strain of, for example, up to about γ = 5 % was applied to the sample. The installation was placed in a heating furnace for tests at temperatures ranging from room temperature (about 20°C) up to 200°C, and the installation was placed into a cooling device for tests conducted at temperatures in the range of from about room temperature to about -196° C.
[00105] It should be noted that thermal treatments (annealing, aging, etc.) of the alloys at different temperatures and/or mechanical treatments (drawing, swaging, etc.) may provide a means of varying the phase transformation temperatures of the alloys. This phenomenon can be associated with the formation of secondary phases and precipitates (distinguished from the B2 phase) during thermal processing. Annealing and/or aging may provide dilution or precipitation of secondary phases. In the presence of secondary phases, the composition of the parent phase may be altered, and thus the phase transformation temperatures of the alloy may be changed. Thus, correction of the phase transformation temperatures may be effected by a further thermal treatment of the alloy. In some cases, the specimens were tested in the as-cast state and/or following one or more annealing treatments. High temperature anneals of the specimens were conducted in a vacuum environment.
Table 2. Melted Alloy Compositions in Atomic Percent (at.%)
Figure imgf000027_0001
Figure imgf000028_0001
[00106] The fabrication method described above can be better understood from the following specific non-limiting examples of the experimental characteristics of several alloys from Table 2 which are intended to illustrate the present invention and to teach a person of the art how to make and use the invention. These examples are not intended to limit the scope of the invention or its protection in any way. [00107] Example 2.1
[00108] According to this example, the specimen designated as alloy #4 in
Table 2 was fabricated as follows. A mixture was prepared from the following elements of the indicated purities: titanium, 99.9%; nickel, 99.99%; gold, 99.95%; iron, 99.95%; and zirconium, 99.99%. The mixture weight was 50 g, and it contained 14.578 grams of titanium, 10.468 grams of nickel, 24.221 grams of gold, 0.1717 gram of iron and 0.5609 gram of zirconium which corresponds to the composition: 49.5 at. % Ti; 29.0 at.% Ni; 20.0 at.% Au; 0.5 at.% Fe; and 1.0 at.% Zr (Ti49 5Ni290Au20 0Fe0 5Zr1 o). The mixture was molten in an arc furnace in a purified argon atmosphere (about 0.4 atm Ar) at a temperature of about 1300°C in a water-cooled copper mold. The arc current was 500 A. Once all the components were melted, the arc was maintained for one additional minute, and then the arc was switched off. The melt was then cooled to a temperature of about 4O0C. To improve the homogeneity of the alloy, the ingot was remelted six times. After cooling between each remelt, the ingot was turned upside down. After the final cooling, bars having a rectangular cross-section of 1.2 mm by 1.2 mm and a length of 26.0 mm were fabricated and tested as described above to evaluate the superelastic behavior of the specimen.
[00109] Fig. 9 illustrates a stress-strain plot for measurements at the temperature of 180C of a Ti49 5Ni29 oAu2o 0Fe0 5Z^ 0 sample prepared as described above. The sample was heated at the temperature of 320°C over 30 minutes before the mechanical test. The plot shows a stress-strain hysteresis which is characteristic of superelastic behavior. As is apparent from the plot, the Ti495Ni29 oAu2O 0Fe05Zr1 0 alloy achieves a recoverable strain of 6.1% in response to the applied torsional stress of 195 MPa at a test temperature of 18°C. [00110] Referring to Fig. 10, stress-strain plots are illustrated for measurements at the temperatures of 17°C and 76°C of the Ti49 5Ni290Au200Fe0 5Zr1 0 sample prepared as described above, and then annealed at the temperature of 800°C for over 120 minutes. Similar to the previous case, the sample was heated at the temperature of 320°C over 30 minutes before the mechanical test. As in Fig. 9, the plot shows a stress-strain hysteresis which is characteristic of superelastic behavior. The Ti49 5Ni290Au20Fe0 5Zri 0 alloy exhibits a recoverable strain of about 6.5% under a torsional stress of 255 MPa at 17°C. At 76°C, the alloy exhibits a recoverable strain of about 6.7% at a torsional stress of
315 MPa.
[00111] Table 3 below provides a summary of the recoverable strain values obtained for sample #4 from the stress-strain tests. Depending on the test temperature, heat treatment, and the maximum applied torsional stress (τmax), recoverable strain values (γresiiience) in the range of from 3.9% to 7.1% were obtained. Also given in the table is the residual plastic component of the deformation, γresiduai-
[00112] It is postulated, based on these data, that a superelastic
Ti49 5Ni29 oAu2O 0Fe0 5Zr1 0 alloy having an austenite finish temperature Af of less than about 17°C may be fabricated as described herein. Accordingly, it is concluded that superelastic behavior may be obtained at human body temperature
(37°C) from a quintary nickel-titanium alloy including Au, Fe, and Zr and having the composition of alloy #4.
Table 3. Recoverable Strain Data for Alloy #4.
Heat Treatment T x experiment? °C *^ ^maximum? -IV-Ix « Y resilience? ' ° Y residual? %
3200C, 30 min. 195 6.1 0.3
18
250 7.1 0.4
60 255 5.8 0.1
116 330 5.6 0.7*
-24 170 3.9 1.0**
8000C, 1 hour, 17 255 6.5 0.5 Slow cooling with
76 315 6.7 0.25 furnace
122 334 5.5 0.2
* At a subsequent heating to a temperature higher than that of the experiment, an additional 0.4% strain recovery is observed. The residual plastic component of the deformation γreSiduai is 0.3% in this case. ** At a subsequent heating to a temperature higher than that of the experiment, full recovery is obtained.
[00113] Example 2.2
[00114] The alloy designated in Table 2 as #13 was fabricated as follows.
A mixture was prepared from the following elements of the indicated purities: titanium, 99.9%; nickel, 99.99%; platinum, 99.99%; iron, 99.95% and zirconium, 99.99%. The mixture weight was 50 g and it contained 16.188 grams of titanium, 11.905 grams of nickel, 19.780 grams of platinum, 1.510 grams of iron and 0.617 gram of zirconium, which corresponds to the composition: 50.0 at. % Ti; 30.0 at.% Ni; 15.0 at.% Pt; 4.0 at.% Fe; and 1.0 at.% Zr (Ti500Ni3O oPt15 OFe4 OZr1 0). [00115] Similar to the previous example, the mixture was molten in an arc furnace in a purified argon atmosphere (about 0.4 atm Ar) at a temperature of about 1300°C in a water-cooled copper mold. The arc current was 500 A. Once all the components were melted, the arc was maintained for one additional minute, and then the arc was switched off. The melt was then cooled to a temperature of about 4O0C. To improve the homogeneity of the alloy, the ingot was remelted six times. After cooling between each remelt, the ingot was turned upside down. [00116] For measurements of mechanical properties (i.e., to obtain σ(ε) curves), bars having a rectangular cross-section of 1.2 mm by 1.2 mm and a length of 26.0 mm were fabricated and tested as in the previous example. [00117] Fig. 11 illustrates a stress-strain plot for measurements at the temperature of 24°C of a Ti5O oNi300Pt15 0Fe4 0Zr1 0 sample prepared as described above, including a further annealing at the temperature of 800°C over 120 minutes followed by cooling to room temperature. Fig. 12 illustrates a stress-strain plot for measurements at the temperature of 40°C of a Ti50 0Ni300Pt15 0Fe4 0Zr1 0 sample prepared as described above without any further heat treatment. Both figures show a stress-strain hysteresis which is characteristic of superelastic behavior. The Ti50 0Ni30 0Ptj5 0Fe40Zri o alloy exhibits a recoverable strain of about 7% under a torsional stress of about 250 MPa at 24°C. At 40°C, the alloy exhibits a recoverable strain of about 6% at a torsional stress of 350 MPa. [00118] It is postulated, based on these data, that a Ti50 0Ni300Pt15 0Fe40Zr1 o alloy having an austenite finish temperature Af of less than about 240C may be fabricated as described herein. Accordingly, it is concluded that superelastic behavior may be obtained at human body temperature (370C) from a quintary nickel-titanium alloy including platinum, iron, and zirconium and having the composition of alloy # 13. [00119] Example 2.3
[00120] The alloy designated in Table 2 as #14 was fabricated as follows. A mixture was prepared from the following elements of the indicated purities: titanium, 99.9%; nickel, 99.99%; gold, 99.95%; iron, 99.95% and zirconium, 99.99%. The mixture weight was 50 g and it contained 17.761 grams of titanium, 16.548 grams of nickel, 14.607 grams of gold, 0.4970 gram of iron and 0.6765 gram of zirconium, which corresponds to the composition: 50.0 at. % Ti; 37.8 at.% Ni; 10.0 at.% Au; 1.2 at.% Fe; and 1.0 at.% Zr (Ti500Ni37 8Au1OoFe1 2Zrj 0). [00121] As in the previous example, the mixture was molten in an arc furnace in a purified argon atmosphere (about 0.4 atm Ar) at a temperature of about 13000C in a water-cooled copper mold. The arc current was 500 A. Once all the components were melted, the arc was maintained for one additional minute, and then the arc was switched off. The melt was then cooled to a temperature of about 4O0C. To improve the homogeneity of the alloy, the ingot was remelted six times. After cooling between each remelt, the ingot was turned upside down. [00122] For measurements of mechanical properties (i.e., to obtain σ(ε) curves), bars having a rectangular cross-section of 1.2 mm by 1.2 mm and a length of 26.0 mm were fabricated and tested as described previously. The tests were carried out at a temperature of 23°C and 39°C.
[00123] Table 4 below provides a summary of the recoverable strain values obtained for sample #14 from the mechanical tests. Depending on the test temperature, heat treatment, and the maximum applied stress (τmax), recoverable strain values (γreSiiιence) ranging from 2.6% to 8.7% were obtained. Also given in the table is the residual plastic component of the deformation, γreSidua!- [00124] It is postulated, based on these data, that a superelastic
Ti50 0Ni37 8Au]o oFej 2Zrj 0 alloy having an austenite finish temperature Af of less than about 23° C may be fabricated as described herein. Accordingly, it is concluded that superelastic behavior may be obtained at human body temperature (37°C) from a quintary nickel-titanium alloy including Au, Fe, and Zr and having the composition of alloy #14.
Table 4. Recoverable Strain Data for Alloy #14.
Figure imgf000033_0001
* - At a subsequent heating to a temperature higher than that of the experiment, an additional 0.15% strain recovery is observed. The residual plastic component of the deformation γresiduai is 0.45% in this case.
[00125] Example 2.4
[00126] According to this example, the specimen designated as alloy #15 in
Table 2 was fabricated as follows. A mixture was prepared from the following elements of the indicated purities: titanium, 99.9%; nickel, 99.99%; gold, 99.95%; and aluminum, 99.999%. The mixture weight was 50 g, and it contained 16.013 grams of titanium, 13.734 grams of nickel, 20.034 grams of gold, and 0.219 gram of aluminum which corresponds to the composition: 49.3 at. % Ti; 34.5 at.% Ni; 15.0 at.% Au; and 1.2 at.% Al (Ti493Ni34 5AUi5 0Al1 2). The mixture was molten in an arc furnace in a purified argon atmosphere (about 0.4 atm Ar) at a temperature of about 1300°C in a water-cooled copper mold. The arc current was 500 A. Once all the components were melted, the arc was maintained for one additional minute, and then the arc was switched off. The melt was then cooled to a temperature of about 40°C. To improve the homogeneity of the alloy, the ingot was remelted six times. After cooling between each remelt, the ingot was turned upside down. After the final cooling, bars having a rectangular cross-section of 1.2 mm by 1.2 mm and a length of 26.0 mm were fabricated and tested as described previously to evaluate the superelastic behavior of the alloy. [00127] Fig. 13 illustrates a stress-strain plot for measurements at the temperature of 24°C of a Ti493Ni34 5Au15 0Al1 2 sample prepared as described above. The sample was annealed at a temperature of 450°C for 2 hours before the mechanical test. The plot shows a stress-strain hysteresis which is characteristic of superelastic behavior. As is apparent from the plot, the Ti493Ni34 5Au15 0Al1 2 alloy achieves a recoverable strain of about 7% in response to an applied torsional stress of 255 MPa at a test temperature of 24° C.
[00128] Table 5 below provides a summary of the recoverable strain values obtained for samples #15/1 and 15/2 from the mechanical tests. Depending on the test temperature, heat treatment, and the maximum applied torsional stress (τmax), recoverable strain values (γreSiiience) in the range of from 1.9% to 7.6% were obtained for the specimens. Also given in the table is the residual plastic component of the deformation, γresiduai-
[00129] It is postulated, based on these data, that a superelastic
Ti49 3Ni34 5Au15 0Al1 2 alloy having an austenite finish temperature Af of less than about 23°C may be fabricated as described herein. Accordingly, it is concluded that superelastic behavior may be obtained at human body temperature (37°C) from a quaternary nickel-titanium alloy including gold and aluminum and having the composition of alloy #15.
Figure imgf000034_0001
Figure imgf000035_0001
* At a subsequent heating at a temperature higher than that of the experiment, an additional 1.15 % strain was recovered. The residual plastic component of the deformation γres,duai is 0.1% in this case.
[00130] Example 2.5
[00131] According to this example, the specimen designated as alloy #16 in
Table 2 was fabricated as follows. A mixture was prepared from the following elements of the indicated purities: titanium, 99.9%; nickel, 99.99%; gold, 99.95%; and chromium, 99.9%%. The mixture weight was 50 g, and it contained 16.257 grams of titanium, 13.416 grams of nickel, 19.975 grams of gold, and 0.351 gram of chromium which corresponds to the composition: 50.2 at. % Ti; 33.8 at.% Ni; 15.0 at.% Au; and 1.0 at.% Cr (Ti502Ni33 8Au15 0Cr1 0). The mixture was molten in an arc furnace in a purified argon atmosphere (about 0.4 atm Ar) at a temperature of about 1300°C in a water-cooled copper mold. The arc current was 500 A. Once all the components were melted, the arc was maintained for approximately one additional minute, and then the arc was switched off. The melt was then cooled to a temperature of about 40°C. To improve the homogeneity of the alloy, the ingot was remelted six times. After cooling between each remelt, the ingot was turned upside down. After the final cooling, bars having a rectangular cross- section of 1.2 mm by 1.2 mm and a length of 26.0 mm were fabricated and tested as described previously to evaluate the superelastic behavior of the alloy. [00132] Fig. 14 illustrates a stress-strain plot for measurements at the temperature of 24°C of a Ti502Ni33 8Au15 0Cri 0 sample prepared as described above. The sample was annealed at a temperature of 800°C for 1 hour and slow- cooled with the furnace before the mechanical test. The plot shows a stress-strain hysteresis which is characteristic of superelastic behavior. As is apparent from the plot, the Ti502Ni33 3Au15 0Cr1 0 alloy achieves a recoverable strain of 6.1% in response to the applied torsional stress of 205 MPa at a test temperature of 42°C. [00133] Table 6 below provides a summary of the recoverable strain values obtained for samples #16 from the stress-strain tests. Depending on the test temperature, heat treatment, and the maximum applied torsional stress (τmax), recoverable strain values (γresiiience) in the range of from 2.9% to 5.6% were obtained for the alloy. Also given in the table is the residual plastic component of the deformation, γresidua|.
[00134] It is postulated, based on these data, that a superelastic
Ti502Ni33 8Au15 (3Cr1 0 alloy having an austenite finish temperature Af of less than about 25° C may be fabricated as described herein. Accordingly, it is concluded that superelastic behavior may be obtained at human body temperature (37°C) from a quaternary nickel-titanium alloy including gold and chromium and having the composition of alloy #16.
Figure imgf000036_0001
* At a subsequent heating to a temperature higher than that of the experiment, an additional strain of 0.5 % was recovered. The residual plastic component of the deformation γres,duai is
0.55% in this case.
** At a subsequent heating to a temperature higher than that of the experiment, an additional strain of 0.3 % was recovered. The residual plastic component of the deformation γresiduai is
0.4% in this case.
*** At a subsequent heating to a temperature higher than that of the experiment, an additional strain of 0.1 % was recovered. The residual plastic component of the deformation γreS]duai is
0.85% in this case.
**** At a subsequent heating to a temperature higher than that of the experiment, the strain was fully recovered.
[00135] Example 3.1
[00136] Electrical resistivity experiments were carried out in an effort to determine the phase transformation temperatures (e.g., Ms, Mf, As, and Af) of alloys 4, 13, 14, 15 and 16. Samples of 15.0 mm by 1.0 mm by 1.0 mm in size were cut from the ingots by electrodischarge machining for the measurements. The surfaces of the samples were mechanically polished, and then, on each side of the sample, current and potential conductors were spot welded. Measurements were carried out using the standard four-terminal method. Current wires were connected to a regulated power supply at a constant current of— IA, and potential conductors were connected to a terminal of a two-coordinate recorder. A thermocouple for measurement and control of the sample temperature was brought to the middle of a sample. The temperature of the device was varied from the boiling temperature of liquid nitrogen (-196°C) to 450°C. Electroresistance measurements within a given temperature range were carried out during heating or cooling of a sample at a rate of about 2-3°C/min. All measurements were carried out in air. If the geometry of a sample was executed with sufficiently precise linear dimensions, then specific electrical resistance p(T) was measured; otherwise, the relative change of electroresistance was determined. Transformation temperatures determined from the electrical resistivity data are presented in Table 7 below for alloy samples 4, 13 and 16 as a function of heat treatment.
[00137] Based on plots of the electrical resistivity data, an austenite finish temperature Af of about 2 TC was obtained for alloy 13, and alloy 16 exhibited values of Af of less than human body temperature (37°C) for three different heat treatment conditions, as indicated in Table 7. Alloy 4 exhibited Af values of 94°C and 96°C in the as-cast and annealed states (see Table 7), although for some heat treatment conditions, no phase transformations were observed during the resistivity measurements. Alloy 15 also showed no phase transformations during resistivity experiments conducted on as-cast (15/1) and annealed (15/2) samples. A portion of alloy 14 appeared to undergo a phase transformation in the range of - 900C to 0°C; however, no phase transformations were observed in the main volume of alloy 14, which was studied in the as-cast state.
Figure imgf000038_0001
[00138] Example 4.1
[00139] The radiopacity of wire samples made from the alloys can be evaluated by using, for example, an x-ray device such as a Siemens
Coroskop Plus/T.O.P. Referring to Fig. 7, exemplary x-ray photographs of wires having a diameter of 400 micrometers made from various Ti-Ni based alloys containing various radiopaque elements are illustrated. Specifically, Fig. 7 illustrates the comparative contrast of x-ray pictures of wire samples made from the TiNiMe alloy having different concentrations of radiopaque elements Me, such as palladium - 10 at.% (sample 1); palladium - 25 at.% (sample 2); palladium - 30 at.% (sample 3); palladium - 35 at.% (sample 4); gold - 8 at.% (sample 5), gold - 14 at.% (sample 6), gold - 35 at.% (sample 7); platinum - 12 at.% (sample 8), platinum - 35 at.% (sample 9). As can be seen, the higher the concentration of the radiopaque element, the higher is the contrast of the x-ray pictures. [00140] A quantitative evaluation of the contrast (on the gray scale) of the x- ray pictures can be made with, for example, the use of a graphics editor such as «Adobe Photoshop-7.0». Fig. 8 illustrates the dependence of the relative contrast of the x-ray pictures shown in Fig. 7 on the amount of the radiopaque alloying element. As can be seen in Fig. 8, if the content of the radiopaque alloying element in the alloy is greater than 15 atomic percent, the radi opacity of the samples increases by more than 50% when compared to the binary Ti5O.oNi5o.o alloy.
[00141] Various articles can be manufactured from the radiopaque alloy of the present invention. In particular, the alloy can be utilized for manufacturing medical devices. At least one component of the medical device may comprise the alloy. The component may have the form of a wire, a tube (i.e., "cannula") or another cast or worked shape, such as a ribbon, button, bar, rivet, sphere, disk, sheet, or foil. Examples of the medical devices that may utilize the radiopaque alloy include, but are not limited to, guide wires, cardiac pacing leads, sutures, prosthetic implants, stents, stent grafts, intraluminal filters, retrieval baskets, graspers, snares, radiopaque markers or marker bands, torqueable catheters, introducer sheaths, aneurysm clips, bone plates and screws, femoral fixation devices, intrauterine contraceptive devices, intramedullary nails and pins, and joints for ankles, elbows, fingers, knees, hips, etc. An exemplary medical device, in particular, a retrieval basket, including at least one component formed of the radiopaque alloy is shown schematically in Fig. 15. [00142] It should be appreciated that the application field of the alloy of the present invention is not limited to medicine. The alloy can also be used for making thermo-sensitive actuating load-bearing elements and other constructions in instrument-making and radio-electronics, etc.
[00143] As such, those skilled in the art to which the present invention pertains, can appreciate that while the present invention has been described in terms of preferred embodiments, the concept upon which this disclosure is based may readily be utilized as a basis for the designing of other structures, systems and processes for carrying out the several purposes of the present invention. [00144] Also, it is to be understood that the phraseology and terminology employed herein are for the purpose of description and should not be regarded as limiting.
[00145] Finally, it should be noted that the word "comprising" as used throughout the appended claims is to be interpreted to mean "including but not limited to."
[00146] It is important, therefore, that the scope of the invention is not construed as being limited by the illustrative embodiments set forth herein. Other variations are possible within the scope of the present invention as defined in the appended claims. Other combinations and sub-combinations of features, functions, elements and/or properties may be claimed through amendment of the present claims or presentation of new claims in this or a related application. Such amended or new claims, whether they are directed to different combinations or directed to the same combinations, whether different, broader, narrower or equal in scope to the original claims, are also regarded as included within the subject matter of the present description.

Claims

CLAIMS:
1. A radiopaque alloy having shape memory and superelastic properties, comprising: titanium at a concentration of from about 48 to about 52 atomic percent; at least one radiopaque alloying element selected from the group consisting of palladium, platinum, and gold, where palladium is at a concentration of from about 15 to about 35 atomic percent and platinum and gold are at a concentration of from about 10 to about 35 atomic percent; at least one additional alloying element selected from the group consisting of iron and cobalt at a concentration of from about 0.5 to about 8 atomic percent; and nickel as a balance.
2. The radiopaque alloy of claim 1, further comprising at least one alloying element selected from selected from the group consisting of aluminum, chromium, and zirconium, where aluminum and chromium are at a concentration of from over 0 to about 2 atomic percent and zirconium is at a concentration of from over 0 to about 6 atomic percent.
3. A radiopaque alloy having shape memory and superelastic properties, comprising: titanium at a concentration of from about 48 to about 52 atomic percent; at least one radiopaque alloying element selected from the group consisting of palladium, platinum, and gold, where palladium is at a concentration of from about 15 to about 35 atomic percent and platinum and gold are at a concentration of from about 10 to about 35 atomic percent; at least one additional alloying element selected from selected from the group consisting of aluminum , chromium, and zirconium, where aluminum and chromium are at a concentration of from over 0 to 2 atomic percent, and zirconium is at a concentration of from over 0 to about 6 atomic percent; and nickel as a balance.
4. The radiopaque alloy of claim 3, further comprising at least one alloying element selected from the group consisting of iron and cobalt at a concentration of from about 0.5 to about 8 atomic percent.
5. A radiopaque alloy having shape memory and superelastic properties, consisting essentially of: titanium at a concentration of from about 48 to about 52 atomic percent; at least one radiopaque alloying element selected from the group consisting of palladium, platinum and gold, where palladium is at a concentration of from about 15 to about 35 atomic percent and platinum and gold are at a concentration of from about 10 to about 35 atomic percent; at least one additional alloying element selected from the group consisting of iron and cobalt at a concentration of from about 0.5 to about 8 atomic percent; at least one further alloying element selected from the group consisting of aluminum, chromium, and zirconium, where aluminum and chromium are at a concentration of from over 0 to about 2 atomic percent, and zirconium is at a concentration of from over 0 to about 6 atomic percent; and boron at a concentration of from about 0.05 atomic percent to about 0.2 atomic percent; and nickel and inevitable impurities as a balance.
6. A radiopaque nickel-titanium alloy comprising: at least one radiopaque alloying element at a concentration of from about 10 at.% to about 20 at.%, the radiopaque alloying element being selected from the group consisting of gold, platinum, and palladium; at least one additional alloying element selected from the group consisting of aluminum, chromium, cobalt, iron, and zirconium, the additional alloying element having a concentration of from about 0.5 at.% to about 4 at.%; titanium at a concentration of from about 48 at. % to about 52 at.%; and the balance nickel; wherein the alloy has a radiopacity greater than that of a binary nickel- titanium alloy and a recoverable strain of at least about 2% upon removal of a deforming stress at about body temperature.
7. The alloy of claim 6, wherein the nickel has a concentration of from about 29 at.% to about 52 at.%
8. The alloy of claim 7, wherein the concentration of the additional alloying element is in the range of from about 0.5 at.% to about 1.2 at.%.
9. The alloy of claim 8, wherein the alloy comprises: gold at a concentration of about 20 at.%; iron at a concentration of about 0.5 at.%; and zirconium at a concentration of about 1 at.%.
10. The alloy of claim 8, wherein the alloy comprises: gold at a concentration of about 10 at.%; iron at a concentration of about 1.2 at.%; and zirconium at a concentration of about 1 at.%.
11. The alloy of claim 8, wherein the alloy comprises: gold at a concentration of about 15 at.%; and aluminum at a concentration of about 1.2 at.%.
12. The alloy of claim 8, wherein the alloy comprises: gold at a concentration of about 15 at.%; and chromium at a concentration of about 1 at.%.
13. The alloy of claim 7, wherein the alloy comprises: platinum at a concentration of about 15 at.%; iron at a concentration of about 4 at.%; and zirconium at a concentration of about 1 at.%.
14. The alloy of claim 6, further comprising boron at a concentration of from about 0.05 at.% to about 0.2 at.%.
15. The alloy of claim 6, wherein the recoverable strain is at least about 5%.
16. The alloy of claim 6, wherein the alloy is superelastic and has an austenite finish temperature at or below 370C.
17. A radiopaque nickel-titanium alloy comprising: a radiopaque constituent comprising one or more radiopaque elements selected from the group consisting of gold, platinum, and palladium, the radi opaque constituent having a concentration of from about 10 at. % to about 35 at. %; an additional constituent comprising one or more additional alloying elements selected from the group consisting of aluminum, chromium, cobalt, iron, and zirconium, the additional constituent having a concentration of from about 0.5 at.% to about 13 at.%, titanium at a concentration of from about 48 at.% to about 52 at.%; and the balance nickel, wherein the alloy has a radiopacity greater than that of a binary nickel- titanium alloy and a recoverable strain of at least about 2% upon removal of a deforming stress at about body temperature.
18. The alloy of claim 17, wherein the nickel has a concentration of from about 29 at.% to about 52 at.%.
19. The alloy of claim 18, wherein the concentration of the radiopaque constituent is from about 10 at.% to about 20 at.% and the concentration of the additional constituent is from about 1 at.% to about 5 at.%.
20. The alloy of claim 19, wherein the radiopaque constituent is gold at a concentration of about 20 at.%, and wherein the additional constituent comprises iron and zirconium, the additional constituent having a concentration of about 1.5 at.%.
21. The alloy of claim 19, wherein the radiopaque constituent is gold at a concentration of about 10 at.%, and wherein the additional constituent comprises iron and zirconium, the additional constituent having a concentration of about 2.2 at.%.
22. The alloy of claim 19, wherein the radiopaque constituent is gold at a concentration of about 15 at.%, and wherein the additional constituent comprises one of aluminum and chromium, the additional constituent having a concentration in the range of from about 1.0 at.% to about 1.2 at.%.
23. The alloy of claim 19, wherein radiopaque constituent is platinum at a concentration of about 15 at.%, and wherein the additional constituent comprises iron and zirconium, the additional constituent having a concentration of about 5 at.%.
24. The alloy of claim 17, wherein the recoverable strain is at least about 5%.
25. The alloy of claim 17, wherein the alloy is superelastic and has an austenite finish temperature at or below 370C.
26. A medical device comprising at least one component comprising a radiopaque alloy having shape memory and superelastic properties, the radiopaque alloy comprising: titanium at a concentration of from about 48 to about 52 atomic percent; at least one radiopaque alloying element selected from the group consisting of palladium, platinum and gold, where palladium is at a concentration of from about 15 to about 35 atomic percent, and platinum and gold are at a concentration of from about 10 to about 35 atomic percent; at least one additional alloying element selected from the group consisting of iron and cobalt at a concentration of from about 0.5 to about 8 atomic percent; and nickel as a balance.
27. The medical device of claim 26, wherein the component comprises at least one of a wire and a cannula.
28. A medical device comprising at least one component comprising a radiopaque alloy having shape memory and superelastic properties, the radiopaque alloy comprising: titanium at a concentration of from about 48 to about 52 atomic percent; at least one radiopaque alloying element selected from the group consisting of palladium, platinum and gold, where palladium is at a concentration of from about 15 to about 35 atomic percent, and platinum and gold are at a concentration of from about 10 to about 35 atomic percent; at least one additional alloying element selected from the group consisting of aluminum, chromium and zirconium, where aluminum and chromium are at a concentration of from over 0 to 2 atomic percent, and zirconium is at a concentration of from over 0 to about 6 atomic percent; and nickel as a balance.
29. The medical device of claim 28, wherein the component comprises at least one of a wire and a cannula.
30. A medical device comprising at least one component comprising a radiopaque alloy having shape memory and superelastic properties, the radiopaque alloy consisting essentially of: titanium at a concentration of from about 48 to about 52 atomic percent; at least one radiopaque alloying element selected from the group consisting of palladium, platinum and gold, where palladium is at a concentration of from about 15 to about 35 atomic percent, and platinum and gold are at a concentration of from about 10 to about 35 atomic percent; at least one additional alloying element selected from the group consisting of iron and cobalt at a concentration of from about 0.5 to about 8 atomic percent; at least one further alloying element element selected from selected from the group consisting of aluminum, chromium and zirconium, where aluminum and chromium are at a concentration of from over 0 to about 2 atomic percent and zirconium is at a concentration of from over 0 to about 6 atomic percent; and nickel and inevitable impurities as a balance.
31. The medical device of claim 30, wherein the component comprises at least one of a wire and a cannula.
32. A medical device comprising at least one component comprising a radiopaque nickel-titanium alloy, the nickel-titanium alloy comprising: at least one radiopaque alloying element at a concentration of from about 10 at.% to about 20 at.%, the radiopaque alloying element being selected from the group consisting of gold, platinum, and palladium; at least one additional alloying element selected from the group consisting of aluminum, chromium, cobalt, iron, and zirconium, the additional alloying element having a concentration of from about 0.5 at.% to about 4 at.%, titanium at a concentration of from about 48 at.% to about 52 at.%; and the balance nickel; wherein the alloy has a radiopacity greater than that of a binary nickel- titanium alloy and a recoverable strain of at least about 2% upon removal of a deforming stress at about body temperature.
33. The medical device of claim 32, wherein the component includes at least one of a wire and a cannula.
34. A medical device comprising at least one component comprising a radiopaque nickel-titanium alloy, the nickel-titanium alloy comprising: a radiopaque constituent comprising one or more radiopaque elements selected from the group consisting of gold, platinum, and palladium, the radiopaque constituent having a concentration of from about 10 at. % to about 35 at. %; an additional constituent comprising one or more additional alloying elements selected from the group consisting of aluminum, chromium, cobalt, iron, and zirconium, the additional constituent having a concentration of from about 0.5 at.% to about 13 at.%, titanium at a concentration of from about 48 at.% to about 52 at.%; and the balance nickel, wherein the alloy has a radiopacity greater than that of a binary nickel- titanium alloy and a recoverable strain of at least about 2% upon removal of a deforming stress at about body temperature.
35. The medical device of claim 34, wherein the component includes at least one of a wire and a cannula.
PCT/US2008/086994 2007-12-21 2008-12-16 Radiopaque alloy and medical device made of this alloy WO2009085757A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP08867178A EP2238270A2 (en) 2007-12-21 2008-12-16 Radiopaque alloy and medical device made of this alloy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1605507P 2007-12-21 2007-12-21
US61/016,055 2007-12-21

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP17156235.8A Previously-Filed-Application EP3296413A1 (en) 2007-12-21 2008-12-16 Radiopaque alloy and medical device made of this alloy

Publications (2)

Publication Number Publication Date
WO2009085757A2 true WO2009085757A2 (en) 2009-07-09
WO2009085757A3 WO2009085757A3 (en) 2009-08-27

Family

ID=40352277

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/086994 WO2009085757A2 (en) 2007-12-21 2008-12-16 Radiopaque alloy and medical device made of this alloy

Country Status (3)

Country Link
US (1) US8801875B2 (en)
EP (2) EP2238270A2 (en)
WO (1) WO2009085757A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2495772B (en) * 2011-10-21 2014-02-12 Univ Limerick Method of forming a sintered nickel-titanium-rare earth (Ni-Ti-RE) alloy
JP6422113B2 (en) * 2014-05-29 2018-11-14 国立研究開発法人物質・材料研究機構 High temperature shape memory alloy and method for producing the same
JP6005119B2 (en) * 2014-10-23 2016-10-12 国立大学法人東京工業大学 Super elastic alloy
US20190276921A1 (en) * 2016-10-21 2019-09-12 Confluent Medical Technologies, Inc. Materials having superelastic properties including related methods of fabrication and design for medical devices
CN113633433A (en) * 2021-10-15 2021-11-12 微创神通医疗科技(上海)有限公司 Vascular implant

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885381A (en) * 1995-07-12 1999-03-23 The Furukawa Electric Co., Ltd. Ni-Ti-Pd superelastic alloy material, its manufacturing method, and orthodontic archwire made of this alloy material
US20040187980A1 (en) * 2003-03-25 2004-09-30 Questek Innovations Llc Coherent nanodispersion-strengthened shape-memory alloys
WO2005102407A1 (en) * 2004-03-30 2005-11-03 Advanced Cardiovascular Systems, Inc. Radiopaque and mri compatible nitinol alloys for medical devices
WO2006066114A1 (en) * 2004-12-15 2006-06-22 Cook Urological Incorporated Radiopaque manipulation devices

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US660228A (en) * 1900-03-26 1900-10-23 Elmer A Sperry Plate or element for storage batteries.
US3620212A (en) 1970-06-15 1971-11-16 Robert D Fannon Jr Intrauterine contraceptive device
JPS4866521A (en) 1971-12-15 1973-09-12
US3786806A (en) 1972-11-22 1974-01-22 A Johnson Thermoconstrictive surgical appliance
USRE28681E (en) 1973-04-02 1976-01-13 High temperature alloys
US3890977A (en) 1974-03-01 1975-06-24 Bruce C Wilson Kinetic memory electrodes, catheters and cannulae
JPS58157935A (en) 1982-03-13 1983-09-20 Hitachi Metals Ltd Shape memory alloy
JPH076047B2 (en) 1982-12-07 1995-01-25 住友電気工業株式会社 Shape memory alloy manufacturing method
US5190546A (en) 1983-10-14 1993-03-02 Raychem Corporation Medical devices incorporating SIM alloy elements
JPS61210142A (en) 1985-03-14 1986-09-18 Mitsui Eng & Shipbuild Co Ltd Ni-ti alloy having superior shock resistance and its manufacture
JPS627839A (en) 1985-07-03 1987-01-14 Sumitomo Electric Ind Ltd Manufacture of niti alloy
US4865663A (en) 1987-03-20 1989-09-12 Armada Corporation High temperature shape memory alloys
EP0353816B1 (en) 1988-08-01 1993-12-22 Matsushita Electric Works, Ltd. Shape memory alloy and electric path protective device utilizing the alloy
EP0395098B1 (en) 1989-04-28 1994-04-06 Tokin Corporation Readily operable catheter guide wire using shape memory alloy with pseudo elasticity
JPH0683726B2 (en) 1990-10-12 1994-10-26 日本精線株式会社 Guide wire for catheter
US5114504A (en) * 1990-11-05 1992-05-19 Johnson Service Company High transformation temperature shape memory alloy
US6682608B2 (en) 1990-12-18 2004-01-27 Advanced Cardiovascular Systems, Inc. Superelastic guiding member
US5341818A (en) 1992-12-22 1994-08-30 Advanced Cardiovascular Systems, Inc. Guidewire with superelastic distal portion
US6165292A (en) 1990-12-18 2000-12-26 Advanced Cardiovascular Systems, Inc. Superelastic guiding member
DE69208837T2 (en) 1991-12-02 1996-10-31 Gen Electric Titanium-aluminum alloys of the gamma type modified with chrome, tantalum and boron
US6277084B1 (en) 1992-03-31 2001-08-21 Boston Scientific Corporation Ultrasonic medical device
US6077368A (en) 1993-09-17 2000-06-20 Furukawa Electric Co., Ltd. Eyeglass frame and fabrication method
US5636641A (en) 1994-07-25 1997-06-10 Advanced Cardiovascular Systems, Inc. High strength member for intracorporeal use
DE69511037T2 (en) 1994-10-28 1999-12-09 Kazuhiro Otsuka Process for the production of shape memory alloys with high transformation temperature
EP0783040B1 (en) 1995-07-10 2001-11-07 Santoku Metal Industry Co., Ltd. Rare earth metal-nickel hydrogen storage alloy, process for producing the same, and anode for nickel-hydrogen rechargeable battery
JP3009623B2 (en) 1996-03-22 2000-02-14 古河電気工業株式会社 Eyeglass frame, manufacturing method and shape adjusting method
US5821664A (en) * 1996-03-28 1998-10-13 Shahinpoor; Moshen Fibrous parallel spring-loaded shape memory alloy rebotic linear
US5927345A (en) 1996-04-30 1999-07-27 Target Therapeutics, Inc. Super-elastic alloy braid structure
US6312454B1 (en) 1996-06-13 2001-11-06 Nitinol Devices & Components Stent assembly
US6312455B2 (en) 1997-04-25 2001-11-06 Nitinol Devices & Components Stent
US6399886B1 (en) 1997-05-02 2002-06-04 General Science & Technology Corp. Multifilament drawn radiopaque high elastic cables and methods of making the same
JPH1136024A (en) * 1997-07-18 1999-02-09 Kazuhiro Otsuka High-temperature-functioning shape memory alloy, and its production
JP3824754B2 (en) * 1997-10-03 2006-09-20 古河電気工業株式会社 Method for producing shape memory alloy cast member
US6503271B2 (en) 1998-01-09 2003-01-07 Cordis Corporation Intravascular device with improved radiopacity
US6557993B2 (en) 1998-07-20 2003-05-06 Optigen S.R.L. Eyeglasses and parts thereof made with specially processed NiTi shape memory alloy
US6325824B2 (en) 1998-07-22 2001-12-04 Advanced Cardiovascular Systems, Inc. Crush resistant stent
US6375458B1 (en) 1999-05-17 2002-04-23 Memry Corporation Medical instruments and devices and parts thereof using shape memory alloys
US6387123B1 (en) 1999-10-13 2002-05-14 Advanced Cardiovascular Systems, Inc. Stent with radiopaque core
US6352515B1 (en) 1999-12-13 2002-03-05 Advanced Cardiovascular Systems, Inc. NiTi alloyed guidewires
US7250058B1 (en) 2000-03-24 2007-07-31 Abbott Cardiovascular Systems Inc. Radiopaque intraluminal stent
US6706053B1 (en) 2000-04-28 2004-03-16 Advanced Cardiovascular Systems, Inc. Nitinol alloy design for sheath deployable and re-sheathable vascular devices
US6572646B1 (en) 2000-06-02 2003-06-03 Advanced Cardiovascular Systems, Inc. Curved nitinol stent for extremely tortuous anatomy
US6626937B1 (en) 2000-11-14 2003-09-30 Advanced Cardiovascular Systems, Inc. Austenitic nitinol medical devices
US20060086440A1 (en) 2000-12-27 2006-04-27 Boylan John F Nitinol alloy design for improved mechanical stability and broader superelastic operating window
US6855161B2 (en) 2000-12-27 2005-02-15 Advanced Cardiovascular Systems, Inc. Radiopaque nitinol alloys for medical devices
US6569194B1 (en) 2000-12-28 2003-05-27 Advanced Cardiovascular Systems, Inc. Thermoelastic and superelastic Ni-Ti-W alloy
US6926733B2 (en) 2001-08-02 2005-08-09 Boston Scientific Scimed, Inc. Method for enhancing sheet or tubing metal stent radiopacity
US6884234B2 (en) 2001-11-01 2005-04-26 Cardio Exodus Partners Foldable and remotely imageable balloon
US20030120181A1 (en) 2001-11-05 2003-06-26 Memry Corporation Work-hardened pseudoelastic guide wires
CA2482451C (en) 2002-04-10 2010-06-08 Karl Storz Endoscopy-America, Inc. Apparatus and method for powering portable battery operated light sources
AU2003262373A1 (en) 2002-04-19 2003-11-03 Salviac Limited A medical device
US6904310B2 (en) 2002-05-07 2005-06-07 Scimed Life Systems, Inc. Customized material for improved radiopacity
US6830638B2 (en) 2002-05-24 2004-12-14 Advanced Cardiovascular Systems, Inc. Medical devices configured from deep drawn nickel-titanium alloys and nickel-titanium clad alloys and method of making the same
ES2197822B1 (en) * 2002-06-18 2005-09-16 Fagor, S. Coop. ELECTRONIC DEVICE FOR THE CONTROL OF A SYNCHRONOUS MOTOR WITH PERMANENT MAGNET ROTOR.
WO2004033016A1 (en) 2002-10-04 2004-04-22 Advanced Cardiovascular Systems, Inc. Radiopaque nitinol alloys for medical devices
US20040143317A1 (en) 2003-01-17 2004-07-22 Stinson Jonathan S. Medical devices
US7942892B2 (en) 2003-05-01 2011-05-17 Abbott Cardiovascular Systems Inc. Radiopaque nitinol embolic protection frame
US7192496B2 (en) 2003-05-01 2007-03-20 Ati Properties, Inc. Methods of processing nickel-titanium alloys
US20040236409A1 (en) 2003-05-20 2004-11-25 Pelton Alan R. Radiopacity intraluminal medical device
US20050131522A1 (en) 2003-12-10 2005-06-16 Stinson Jonathan S. Medical devices and methods of making the same
JP4351560B2 (en) 2004-03-05 2009-10-28 Necトーキン株式会社 Balloon expandable superelastic stent
US7344560B2 (en) 2004-10-08 2008-03-18 Boston Scientific Scimed, Inc. Medical devices and methods of making the same
JP5009163B2 (en) 2004-11-10 2012-08-22 ボストン サイエンティフィック リミテッド Trauma avoidance stent with reduced deployment force, manufacturing method thereof, and stent delivery and deployment system
US7641983B2 (en) 2005-04-04 2010-01-05 Boston Scientific Scimed, Inc. Medical devices including composites

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885381A (en) * 1995-07-12 1999-03-23 The Furukawa Electric Co., Ltd. Ni-Ti-Pd superelastic alloy material, its manufacturing method, and orthodontic archwire made of this alloy material
US20040187980A1 (en) * 2003-03-25 2004-09-30 Questek Innovations Llc Coherent nanodispersion-strengthened shape-memory alloys
WO2005102407A1 (en) * 2004-03-30 2005-11-03 Advanced Cardiovascular Systems, Inc. Radiopaque and mri compatible nitinol alloys for medical devices
WO2006066114A1 (en) * 2004-12-15 2006-06-22 Cook Urological Incorporated Radiopaque manipulation devices

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 199916 Thomson Scientific, London, GB; AN 1999-186659 XP002520197 & JP 11 036024 A (FURUKAWA ELECTRIC CO LTD) 9 February 1999 (1999-02-09) *
ECKELMEYER ET AL: "The effect of alloying on the shape memory phenomenon in nitinol" SCRIPTA METALLURGICA, ELSEVIER SCIENCE LTD., KIDLINGTON, GB, vol. 10, no. 8, 1 August 1976 (1976-08-01), pages 667-672, XP024133911 ISSN: 0036-9748 [retrieved on 1976-08-01] *
JAN VAN HUMBEECK: "SMART MATERIALS. Chapter 2.4 Shape Memory Alloys" 20 November 2008 (2008-11-20), CRC PRESS , USA , XP008103933 ISBN: 978 1 420 04372 3 paragraph [20.4.2.3] - paragraph [20.4.2.4] *
RONALD NOEBE: "ADVANCED STRUCTURAL MATERIALS [...]. Chapter 7: NiTi-Based High-Temperature Shape-Memory Alloys..." 21 December 2006 (2006-12-21), CRC PRESS , USA , XP008103927 ISBN: 978 1 574 44634 0 page 157, paragraph 7.4.1.2; figure 7.10 paragraphs [7.4.2] - [7.4.6] page 163, lines 26-32 *
YANG W S ET AL: "Ductilization of Ti-Ni-Pd shape memory alloys with boron additions" SCRIPTA METALLURGICA ET MATERIALIA, OXFORD, GB, vol. 28, no. 2, 15 January 1993 (1993-01-15), pages 161-165, XP024182201 ISSN: 0956-716X [retrieved on 1993-01-15] *

Also Published As

Publication number Publication date
EP2238270A2 (en) 2010-10-13
WO2009085757A3 (en) 2009-08-27
US20090162243A1 (en) 2009-06-25
EP3296413A1 (en) 2018-03-21
US8801875B2 (en) 2014-08-12

Similar Documents

Publication Publication Date Title
EP2500443B1 (en) NI-TI semi-finished products and related methods
Maeshima et al. Shape memory properties of biomedical Ti-Mo-Ag and Ti-Mo-Sn alloys
CA2658580C (en) Nickel-titanium alloy including a rare earth element
EP1352979B1 (en) Super-elastic titanium alloy for medical uses
US6786984B1 (en) Ternary alloy and apparatus thereof
US20090010796A1 (en) Long fatigue life nitinol
WO2006081011A2 (en) Nitinol alloy for with good mechanical stability and a good superelastic operating window
US8801875B2 (en) Radiopaque alloy and medical device made of this alloy
WO2005098064A2 (en) Β titanium compositions and methods of manufacture thereof
WO2006007434A1 (en) β TITANIUM COMPOSITIONS AND METHODS OF MANUFACTURE THEREOF
KR101837872B1 (en) Superelastic alloy
Oshida et al. Nickel-titanium materials: biomedical applications
JP2009097064A (en) Ti-BASE ALLOY
JP2008240006A (en) Pd-BASED SHAPE MEMORY ALLOY
JP2004197112A (en) Method of producing biological superelastic titanium alloy
WO1999049091A1 (en) Ti-V-Al BASED SUPERELASTICITY ALLOY
EP4107303B1 (en) Use of bioresorbable pseudoelastic fe-mn-x-y alloys for medical implants
US20240002982A1 (en) Superelastic alloys
JP2004124156A (en) METHOD FOR MANUFACTURING SUPERELASTIC TiNbSn ALLOY FOR ORGANISM
JP3933623B2 (en) Method for producing superelastic titanium alloy for living body and titanium alloy for superelasticity
Sholihin et al. Effect of annealing on surface oxidation of Ti-50.8 at% Ni shape memory alloy
Mukunda et al. Effect of low temperature annealing on the properties of nano Ni–Ti alloys
Williams Nickel and Nickel Alloys
JPH089747B2 (en) Bio-functional alloy
JP2005105404A6 (en) Method for producing superelastic titanium alloy for living body and titanium alloy for superelasticity

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08867178

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008867178

Country of ref document: EP